<!DOCTYPE html>
<html>
<head>

<script id="f5_cspm">
(function(){var f5_cspm={f5_p:'HFGPELEJDBMIHDJGLFEPJDEKOIEMJMBKBBCBFDKIHHNBLDKMAFMMDHNOIGPAAEAPDHKLECDDEFOANLHCAECHDOCFJDPGMBNKHALPBLKAHEEOMGOOOJKOEKOMJKIBFLMA',setCharAt:function(str,index,chr){if(index>str.length-1)return str;return str.substr(0,index)+chr+str.substr(index+1);},get_byte:function(str,i){var s=(i/16)|0;i=(i&15);s=s*32;return((str.charCodeAt(i+16+s)-65)<<4)|(str.charCodeAt(i+s)-65);},set_byte:function(str,i,b){var s=(i/16)|0;i=(i&15);s=s*32;str=f5_cspm.setCharAt(str,(i+16+s),String.fromCharCode((b>>4)+65));str=f5_cspm.setCharAt(str,(i+s),String.fromCharCode((b&15)+65));return str;},set_latency:function(str,latency){latency=latency&0xffff;str=f5_cspm.set_byte(str,32,(latency>>8));str=f5_cspm.set_byte(str,33,(latency&0xff));str=f5_cspm.set_byte(str,27,2);return str;},wait_perf_data:function(){try{var wp=window.performance.timing;if(wp.loadEventEnd>0){var res=wp.loadEventEnd-wp.navigationStart;if(res<60001){var cookie_val=f5_cspm.set_latency(f5_cspm.f5_p,res);window.document.cookie='aaaaaaaaaaaaaaa='+encodeURIComponent(cookie_val)+';path=/';}
return;}}
catch(err){return;}
setTimeout(f5_cspm.wait_perf_data,100);return;},go:function(){var chunk=window.document.cookie.split(/\s*;\s*/);for(var i=0;i<chunk.length;++i){var pair=chunk[i].split(/\s*=\s*/);if(pair[0]=='f5_cspm'){if(pair[1]=='1234'){var d=new Date();d.setTime(d.getTime()-1);window.document.cookie='f5_cspm=;expires='+d.toUTCString()+';path=/;';setTimeout(f5_cspm.wait_perf_data,100);}}}}}
f5_cspm.go();}());
</script>
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta charset="utf-8">
<title>DailyMed - KETEK- telithromycin tablet, film coated</title>
<!--[if lt IE 9]>
        <script src="/dailymed/scripts/html5shiv.min.js"></script>
    <![endif]-->

<script src="/dailymed/scripts/modernizr-2.0.6.min.js">
</script>
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/skeleton.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/jquery.jqzoom.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/style.min.css?v=2">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/header-search.min.css">
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive.min.css">
<link rel="stylesheet" type="text/css" media="print" href=
"/dailymed/css/print.min.css"><!--[if !IE]><!-->
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive-tables.min.css"><!--<![endif]-->
<link rel="icon" href="/dailymed/images/favicons/favicon.ico" type=
"image/x-icon">
<link rel="shortcut icon" href=
"/dailymed/images/favicons/favicon.ico" type="image/x-icon">
<link rel="apple-touch-icon" sizes="57x57" href=
"/dailymed/images/favicons/apple-touch-icon-57x57.png">
<link rel="apple-touch-icon" sizes="114x114" href=
"/dailymed/images/favicons/apple-touch-icon-114x114.png">
<link rel="apple-touch-icon" sizes="72x72" href=
"/dailymed/images/favicons/apple-touch-icon-72x72.png">
<link rel="apple-touch-icon" sizes="144x144" href=
"/dailymed/images/favicons/apple-touch-icon-144x144.png">
<link rel="apple-touch-icon" sizes="60x60" href=
"/dailymed/images/favicons/apple-touch-icon-60x60.png">
<link rel="apple-touch-icon" sizes="120x120" href=
"/dailymed/images/favicons/apple-touch-icon-120x120.png">
<link rel="apple-touch-icon" sizes="76x76" href=
"/dailymed/images/favicons/apple-touch-icon-76x76.png">
<link rel="apple-touch-icon" sizes="152x152" href=
"/dailymed/images/favicons/apple-touch-icon-152x152.png">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-196x196.png" sizes="196x196">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-160x160.png" sizes="160x160">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-96x96.png" sizes="96x96">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-16x16.png" sizes="16x16">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-32x32.png" sizes="32x32">
<meta name="msapplication-config" content=
"/dailymed/images/favicons/browserconfig.xml">
<meta name="msapplication-TileColor" content="#da532c">
<meta name="msapplication-TileImage" content=
"/dailymed/images/favicons/mstile-144x144.png">
<meta name="description" content="">
<meta name="keywords" content="">
<meta name="robots" content="noimageindex, noodp, noydir">
<meta name="viewport" id="viewport" content=
"width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0"><!-- Magnific Popup core CSS file -->
<link rel="stylesheet" href="/dailymed/css/magnific-popup.min.css">
<meta name="format-detection" content="telephone=no">
</head>
<body class="inner drug-info">
<div class="container_1000 bg_shadow">
<div style="width: 0; height: 0;"><a href="#" id=
"top-of-page"></a></div>
<header>
<div class="topHeader">
<ul id="skip">
<li><a href="#skip-main-content">Skip to Main Content</a></li>
</ul>
<nav class="topHeaderNav">
<div class="topNIHLogo mobileview"><a href="http://www.nih.gov"
class="top-logo" title="National Institutes of Health" target=
"_blank"><img src="/dailymed/images/nih-toplogo.png" alt=
"NIH Logo"></a> <a href="//www.nlm.nih.gov" title=
"U.S. National Library of Medicine" target="_blank">U.S. National
Library of Medicine</a></div>
<div class="container">
<div class="sixteen columns">
<div class="topNIHLogo"><a href="http://www.nih.gov" title=
"National Institutes of Health" target="_blank"><img src=
"/dailymed/images/nih-toplogo.png" alt="NIH Logo"></a> <a href=
"//www.nlm.nih.gov" title="U.S. National Library of Medicine"
target="_blank">U.S. National Library of Medicine</a></div>
<ul>
<li class="safety"><a title="Report Adverse Events" href=
"//www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report
Adverse Events</a> <span>|</span><a title=
"FDA Safety Reporting and Recalls" href=
"http://www.fda.gov/Safety/Recalls" target=
"_blank">Recalls</a></li>
</ul>
</div>
</div>
</nav>
<div class="divider"></div>
</div>
<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png"
alt="DailyMed"></div>
<div class="bottomHeader">
<div class="header-image">
<div class="mobile-menu-btn closed hasjs" tabindex="0"></div>
<div class="mobile-menu">
<div class="mobile-menu-container">
<div class="pro-menu active">
<div class="first half">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/about-dailymed.cfm">About Dailymed</a></li>
<li><a href="/dailymed/contact-us.cfm">Contact Us</a></li>
<li>Safety Reporting &amp; Recalls
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/">Report
Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey
Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
</ul>
</div>
<div class="last half">
<ul>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-all-mapping-files.cfm">Articles &amp;
Presentations</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</div>
</div>
<a href="/dailymed/index.cfm" class="logo" title=
"DailyMed">DailyMed</a>
<div class="header-search-container">
<div id="header-search">
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all" value="all"> <label for=
"labeltype-all">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human" value="human"> <label for=
"labeltype-human">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal" value="animal"> <label for=
"labeltype-animal">Animal Drugs</label></li>
<li class="more-ways" id="header-search-more-ways"><a href="#" id=
"more-ways-button" class="more-ways-label">More ways to search</a>
<ul id="more-ways-dropdown" class="dropdown" style="display:none;">
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Label Archives</a></li>
<li><a class="external-link" href="http://pillbox.nlm.nih.gov"
target="_blank">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
</div>
</div>
<div class="mobile-search-btn" tabindex="0"></div>
<div class="header-bg"></div>
<div class="divider"></div>
</div>
<div class="bottomHeaderContent">
<div class="search mobile-search">
<div class="divider_10 nomargin mobileview"></div>
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all-2" value="all"> <label for=
"labeltype-all-2">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human-2" value="human"> <label for=
"labeltype-human-2">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal-2" value="animal"> <label for=
"labeltype-animal-2">Animal Drugs</label></li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchToolsQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
<div class="divider"></div>
<nav class="bottomHeaderNav"><noscript>
<div class="tabletnav no-js">
<div class="col">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</noscript>
<ul class="webview hasjs">
<li><a href="/dailymed/index.cfm" title="Home">Home</a></li>
<li><a href="#" title="News">News</a>
<ul class="sub-menu">
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm" title=
"FDA Guidances &amp; Info">FDA Guidances &amp; Info</a></li>
<li><a href="#" title=
"Structured Product Labeling (SPL) resources for industry professionals.">
NLM SPL Resources</a>
<ul class="sub-menu">
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><a href="#" title="Application Development Support">Application
Development Support</a>
<ul class="sub-menu">
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
<ul class="tabletview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li class="viewmore"><a href="#" title="View More">View More</a>
<ul>
<li><span>News</span>
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><span>Safety Reporting and Recalls</span>
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="//www.fda.gov/Safety/Recalls" target="_blank">FDA
Saftey Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li><span>NLM SPL Resources</span>
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><span>Application Development Support</span>
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
</li>
<li class="mobileview viewmore" tabindex="0"><a title="View More"
href="#">More ways to search</a>
<ul>
<li tabindex="0"><a title="Browse Drug Classes" href=
"/dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>
<li tabindex="0"><a title="Label Archives" href=
"/dailymed/archives/index.cfm">Label Archives</a></li>
<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool"
href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
<ul class="mobileview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li tabindex="0" class="viewmore"><a href="#" title=
"View More">View More</a>
<ul>
<li tabindex="0"><a href="/dailymed/browse-drug-classes.cfm" title=
"Browse Drug Classes">Browse Drug Classes</a></li>
<li tabindex="0"><a href="/dailymed/archives/index.cfm" title=
"Label Archives">Label Archives</a></li>
<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title=
"Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</nav>
<div class="divider_10 nomargin"></div>
</div>
</div>
<div class="divider"></div>
</div>
</header>
<div id="skip-main-content"></div>
<div class="container">
<div class="main-content">
<div class="header long">
<div class="header-top">
<h1>Label: <span class="long-title">KETEK- telithromycin tablet,
film coated<br></span></h1>
</div>
<ul class="tools">
<li class="rss"><a href="#modal-label-rss" class="modal-open">Label
RSS</a></li>
<li class="share">Share <noscript>: JavaScript needed for Sharing
tools</noscript> <!-- AddThis Button BEGIN -->
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AKETEK%2D%20Telithromycin%20Tablet%2C%20Film%20Coated%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D4471223e%2D9023%2D457e%2Dbe2e%2D8e4e0c2d94d1%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="display: block;"><span style=
"left: -9999px; position: absolute;">Bookmark &amp;
Share</span><img style="width:17px" src=
"/dailymed/images/addthis-image.jpg"></a></div>
<script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <!-- AddThis Button END --></li>
</ul>
</div>
<div class="four columns sidebar" id="leftmenu">
<section>
<article>
<div class="w-photos">
<div class="mod drug-photos">
<h2><a>View Package Photos</a></h2>
<ul>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=ketek-02.jpg&amp;setid=4471223e-9023-457e-be2e-8e4e0c2d94d1"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="0"><img id="zoom_1" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=ketek-02.jpg&amp;setid=4471223e-9023-457e-be2e-8e4e0c2d94d1"
src=
"image.cfm?type=img&amp;name=ketek-02.jpg&amp;setid=4471223e-9023-457e-be2e-8e4e0c2d94d1"
data-photo-type="package"> </a></li>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=ketek-03.jpg&amp;setid=4471223e-9023-457e-be2e-8e4e0c2d94d1"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="1"><img id="zoom_2" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=ketek-03.jpg&amp;setid=4471223e-9023-457e-be2e-8e4e0c2d94d1"
src=
"image.cfm?type=img&amp;name=ketek-03.jpg&amp;setid=4471223e-9023-457e-be2e-8e4e0c2d94d1"
data-photo-type="package"> </a></li>
</ul>
</li>
</ul>
</div>
<div class="mod drug-photos">
<h2><a>VIEW DRUG PHOTOS</a></h2>
<div class="no-pill-photo-warning-drug-info">DailyMed is no longer
displaying pill images from RxImage. For more information, <a href=
"#no-pill-photo-warning-modal" class="modal-open">click
here</a>.</div>
</div>
</div>
<div class="mod-wrap">
<div class="mod blue-list page-jump">
<h2><a href="#drug-information">Drug Label Info</a></h2>
</div>
<div class="mod blue-list orange">
<h2><a href="#">Safety</a></h2>
<ul>
<li><a class="tip" rel="tooltip" title=
"A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects."
href="#boxedwarning">Boxed Warnings</a></li>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls/" target=
"_blank">FDA Safety Recalls</a></li>
<li><a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22telithromycin%22+%29"
target="_blank">Presence in Breast Milk</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">Related Resources</a></h2>
<ul>
<li><a href=
"//vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=telithromycin"
target="_blank">Medline Plus</a></li>
<li><a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=telithromycin"
target="blank">Clinical Trials</a></li>
<li><a href="#" id="pubmed-menu">PubMed</a>
<ul>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=telithromycin[All%20Fields]"
title="Link opens new window for All Citations" target="pubmed">All
Citations</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=telithromycin/AE"
title="Link opens new window for Adverse Effects" target=
"pubmed">Adverse Effects</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=telithromycin/TU"
title="Link opens new window for Therapeutic Use" target=
"pubmed">Therapeutic Use</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=telithromycin/PD"
title="Link opens new window for Pharmacology" target=
"pubmed">Pharmacology</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=telithromycin[All%20Fields]%20AND%20Clinical%20Trial[ptyp]"
title="Link opens new window for Clinical Trials" target=
"pubmed">Clinical Trials</a></li>
</ul>
</li>
<li><a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=APRD00483&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">More Info For This Drug</a></h2>
<ul>
<li><a href="#modal-label-archives" class="modal-open">View Label
Archives</a></li>
<li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>
<li><a href="#modal-label-rss" class="modal-open">Get Label RSS
Feed</a></li>
</ul>
</div>
</div>
</article>
</section>
</div>
<div class="content-wide">
<article>
<ul class="drug-information">
<li><strong><a class="tip" rel="tooltip" title=
"&lt;b&gt;NDC (National Drug Code)&lt;/b&gt; - Each drug product is assigned this unique number which can be found on the drug's outer packaging."
href="#">NDC Code(s):</a></strong> <span id=
"item-code-s">0088-2223-20, 0088-2225-41</span></li>
<li style="list-style: none"><span id="item-code-s"></span></li>
<li><span id="item-code-s"></span></li>
<li><span id="item-code-s"><strong>Packager:</strong>
sanofi-aventis U.S. LLC</span></li>
</ul>
<ul class="drug-information">
<li><span id="item-code-s"><strong>Category:</strong> <span id=
"category" class="orangetext">HUMAN PRESCRIPTION DRUG
LABEL</span></span></li>
<li><strong>DEA Schedule:</strong> <span id=
"dea-schedule">None</span></li>
<li><strong>Marketing Status:</strong> <span id=
"marketing-status">New Drug Application</span></li>
</ul>
<div id="drug-information" class="toggle">
<h2><a id="druglabel"></a>Drug Label Information</h2>
<p class="date">Updated December 14, 2015</p>
<p class="orangetext">If you are a consumer or patient please visit
<a class="audience-context-switch consumer" href=
"/dailymed/drugInfo.cfm?setid=4471223e-9023-457e-be2e-8e4e0c2d94d1&amp;audience=consumer">
this version.</a></p>
<ul class="tools">
<li class="download">Download DRUG LABEL INFO: <a download=""
class="pdf" href=
"/dailymed/getFile.cfm?setid=4471223e-9023-457e-be2e-8e4e0c2d94d1&amp;type=pdf&amp;name=4471223e-9023-457e-be2e-8e4e0c2d94d1"
target="_blank">PDF</a> <a download="" class="xml" href=
"/dailymed/getFile.cfm?setid=4471223e-9023-457e-be2e-8e4e0c2d94d1&amp;type=zip&amp;name=KETEK"
target="_blank">XML</a></li>
<li class="medguide">Medication Guide: <a href=
"/dailymed/medguide.cfm?setid=4471223e-9023-457e-be2e-8e4e0c2d94d1"
target="_blank">HTML</a></li>
<li class="print"><a href=
"/dailymed/fda/fdaDrugXsl.cfm?setid=4471223e-9023-457e-be2e-8e4e0c2d94d1&amp;type=display"
target="_blank">Print Drug Label Info</a></li>
</ul>
<div class="drug-label-sections">
<div class="control-nav show-js"><a class="open-all" href="#">View
All Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
<ul>
<li id="boxedwarning"><a href="#">BOXED WARNING</a><a class=" tip"
rel="tooltip" href="#" title=
"A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects.">(What
is this?)</a>
<div class="Warning toggle-content open"><a name="BOX" id=
"BOX"></a> <a name="section-1" id="section-1"></a>
<h1><span class="Emphasis">WARNING: CONTRAINDICATION IN MYASTHENIA
GRAVIS</span></h1>
<p class="First"><span class="Bold">There have been reports of
fatal and life-threatening respiratory failure in patients with
myasthenia gravis associated with the use of KETEK. <span class=
"Italics">[see <a href="#S4.1">Contraindications
(4.1)</a>]</span></span></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">HIGHLIGHTS OF PRESCRIBING INFORMATION</a>
<div id="Highlights" class=" Highlights toggle-content closed">
<div class="HighlightsDisclaimer">These highlights do not include
all the information needed to use KETEK <span class="Sup">®</span>
safely and effectively. See full prescribing information for
KETEK.<br>
<br>
KETEK (telithromycin) tablets, for oral use<br>
Initial U.S. Approval: 2004</div>
<div class="Warning">
<div>
<h1 class="Warning"><span class="Bold">WARNING: CONTRAINDICATION IN
MYASTHENIA GRAVIS</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing
information for complete boxed warning</span></h1>
<p class="Highlighta"><span class="Bold">Fatal and life-threatening
respiratory failure has been reported in patients with myasthenia
gravis associated with use of KETEK <span class="Italics">(<a href=
"#S4.1">4.1</a>)</span></span></p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<table class="Noautorules" width="100%">
<colgroup>
<col align="left" valign="top" width="80%">
<col align="right" valign="top" width="20%"></colgroup>
<tbody class="Headless">
<tr>
<td align="left">Warnings and Precautions (<a href=
"#S5.2">5.2</a>)</td>
<td align="right">10/15</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">KETEK is a ketolide antibacterial indicated
for the treatment of community-acquired pneumonia of mild to
moderate severity. (<a href="#S1">1</a>)</p>
<p class="Highlighta">To reduce the development of drug-resistant
bacteria and maintain the effectiveness of KETEK and other
antibacterial drugs, KETEK should be used only to treat infections
that are proven or strongly suspected to be caused by bacteria.
(<a href="#S1">1</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul class="Disc">
<li>800 mg taken orally once daily, for 7–10 days. (<a href=
"#S2.1">2.1</a>)</li>
<li>In patients with severe renal impairment including dialysis:
600 mg once daily (<a href="#S2.2">2.2</a>)</li>
<li>In patients with severe renal impairment and with coexisting
hepatic impairment: 400 mg once daily. (<a href=
"#S2.2">2.2</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">Tablets: 300 mg and 400 mg (<a href=
"#S3">3</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<ul class="Disc">
<li>Patients with myasthenia gravis. (<a href="#S4.1">4.1</a>)</li>
<li>History of hepatitis or jaundice with KETEK or any macrolide.
(<a href="#S4.2">4.2</a>)</li>
<li>Known hypersensitivity to KETEK or any macrolide. (<a href=
"#S4.3">4.3</a>)</li>
<li>Concomitant administration of KETEK with cisapride or pimozide.
(<a href="#S4.4">4.4</a>)</li>
<li>Concomitant administration of KETEK and colchicine in patients
with renal or hepatic impairment. (<a href="#S4.5">4.5</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<ul>
<li><span class="Underline">Hepatotoxicity</span>: Fatal acute
liver injury has been reported. Discontinue immediately if signs
and symptoms of hepatitis occur. (<a href="#S5.1">5.1</a>)</li>
<li><span class="Underline">Prolongation of QTc interval</span>:
Increased risk for ventricular arrhythmias, including ventricular
tachycardia and torsade de pointes with fatal outcomes. Avoid use
in patients with known QTc prolongation, hypokalemia, and with
class IA and III antiarrhythmics. (<a href="#S5.2">5.2</a>)</li>
<li><span class="Underline">Visual disturbances and loss of
consciousness</span>: KETEK may impair accommodation. Avoid driving
or other hazardous activity. (<a href="#S5.3">5.3</a>)</li>
<li><span class="Underline">Serious Adverse Reactions with
Concomitant Drugs:</span> Fatalities with colchicine,
rhabdomyolysis with HMG-CoA reductase inhibitors, and hypotension
with calcium channel blockers have been reported. Avoid concomitant
use. Monitor for toxicity and consider dose reduction of the
concomitant medication, if concomitant use is unavoidable (<a href=
"#S5.4">5.4</a>, <a href="#S7">7</a>)</li>
<li><span class="Underline"><span class="Italics">Clostridium
difficile</span>-associated diarrhea</span>: evaluate if diarrhea
occurs. (<a href="#S5.5">5.5</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (2% or
greater) are diarrhea, nausea, dizziness, and vomiting (<a href=
"#S6.1">6.1</a>)</p>
<br>
<p class="Highlighta"><span class="Bold">To report SUSPECTED
ADVERSE REACTIONS, contact sanofi-aventis U.S. LLC at
1-800-633-1610 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch</span></p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<ul class="Disc">
<li><span class="Underline">CYP3A4 inducers</span>: Decreased KETEK
levels resulting in loss of efficacy. Avoid concomitant use.
(<a href="#S7">7</a>)</li>
<li><span class="Underline">CYP3A4 inhibitors</span>: Increased
KETEK levels and risk of adverse reactions. Avoid concomitant use.
(<a href="#S7">7</a>)</li>
<li><span class="Underline">Drugs metabolized via CYP3A4
pathway</span>: KETEK may increase levels of these concomitant
medications. Avoid concomitant use. If not possible, monitor for
concomitant drug toxicity. Consider dosage reduction. (<a href=
"#S7">7</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC
POPULATIONS</span></h1>
<div>
<p class="Highlighta">The safety and effectiveness under the age of
18 years has not been established. (<a href="#S8.4">8.4</a>)</p>
</div>
</div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING
INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 12/2015</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">FULL PRESCRIBING INFORMATION: CONTENTS*</a>
<div id="Index" class=" Index toggle-content closed">
<h1><a href="#section-1" class="toc"><span class=
"Emphasis">WARNING: CONTRAINDICATION IN MYASTHENIA
GRAVIS</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND
USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND
ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended
Dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosage in Patients with
Renal and/or Hepatic Impairment</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND
STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Myasthenia
Gravis</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Hepatitis</a></h2>
<h2><a href="#section-4.3" class="toc">4.3
Hypersensitivity</a></h2>
<h2><a href="#section-4.4" class="toc">4.4
Cisapride/Pimozide</a></h2>
<h2><a href="#section-4.5" class="toc">4.5 Colchicine</a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND
PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Hepatotoxicity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 QTc
Prolongation</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Visual Disturbances and
Loss of Consciousness</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Serious Adverse
Reactions with Concomitant Drugs</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class=
"Italics">Clostridum difficile</span>-Associated Diarrhea</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Development of Drug
Resistant Bacteria</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials
Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing
Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC
POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Renal and/or Hepatic
Impairment</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL
PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of
Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3
Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL
TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis,
Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology
and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">15 References</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND
HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING
INFORMATION</a></h1>
<dl class="Footnote">
<dt><a name="footnote-content" href="#footnote-reference-content"
id="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing
information are not listed.</dd>
</dl>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">1 INDICATIONS AND USAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34067-9"><a name="S1" id="S1"></a> <a name="section-1" id=
"section-1"></a>
<p class="First">KETEK is indicated for the treatment of
community-acquired pneumonia (of mild to moderate severity) due to
<span class="Italics">Streptococcus pneumoniae</span>, (including
multi-drug resistant <span class="Italics">S. pneumoniae</span>
[MDRSP<a class="Sup" href="#footnote-1" name="footnote-reference-1"
id="footnote-reference-1">1</a>]), <span class=
"Italics">Haemophilus influenzae</span>, <span class=
"Italics">Moraxella catarrhalis</span>, <span class=
"Italics">Chlamydophila pneumoniae</span>, or <span class=
"Italics">Mycoplasma pneumoniae</span>, for patients 18 years or
older.</p>
<p>To reduce the development of drug-resistant bacteria and
maintain the effectiveness of KETEK and other antibacterial drugs,
KETEK should be used only to treat infections that are proven or
strongly suspected to be caused by susceptible bacteria. When
culture and susceptibility information are available, they should
be considered in selecting or modifying antibacterial therapy. In
the absence of such data, local epidemiology and susceptibility
patterns may contribute to the empiric selection of therapy.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a href="#footnote-reference-1" name="footnote-1" id=
"footnote-1">1</a></dt>
<dd>MDRSP, Multi-drug resistant <span class="Italics">Streptococcus
pneumoniae</span> includes isolates known as PRSP
(penicillin-resistant <span class="Italics">Streptococcus
pneumoniae</span>), and are isolates resistant to two or more of
the following antibacterials: penicillin, 2 <span class=
"Sup">nd</span> generation cephalosporins, e.g., cefuroxime,
macrolides, tetracyclines and trimethoprim/sulfamethoxazole.</dd>
</dl>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">2 DOSAGE AND ADMINISTRATION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34068-7"><a name="S2" id="S2"></a> <a name="section-2" id=
"section-2"></a>
<div class="Section" data-sectioncode="42229-5"><a name="S2.1" id=
"S2.1"></a> <a name="section-2.1" id="section-2.1"></a>
<h2>2.1 Recommended Dosage</h2>
<p class="First">The dosage of KETEK tablets is 800 mg (2 tablets
of 400 mg) taken orally once daily for 7–10 days in patients 18
years or older. KETEK tablets can be administered with or without
food.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S2.2" id=
"S2.2"></a> <a name="section-2.2" id="section-2.2"></a>
<h2>2.2 Dosage in Patients with Renal and/or Hepatic
Impairment</h2>
<p class="First">In the presence of severe renal impairment
(CL<span class="Sub">CR</span> less than 30 mL/min), including
patients who need dialysis, reduce the dosage of KETEK to 600 mg
once daily. In patients undergoing hemodialysis, give KETEK after
the dialysis session on dialysis days. <span class="Italics">[see
<a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span></p>
<p>In the presence of severe renal impairment (CL<span class=
"Sub">CR</span> less than 30 mL/min), with coexisting hepatic
impairment, reduce the dosage of KETEK to 400 mg once daily.
Patients with mild or moderate renal impairment (CL<span class=
"Sub">CR</span> of 30 mL/min or more) with or without coexisting
hepatic impairment do not require a dosage adjustment. No dosage
adjustments of KETEK are necessary in patients with hepatic
impairment alone. <span class="Italics">[see <a href=
"#S12.3">Clinical Pharmacology (12.3)</a>]</span></p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">3 DOSAGE FORMS AND STRENGTHS</a>
<div class="Section toggle-content closed" data-sectioncode=
"43678-2"><a name="S3" id="S3"></a> <a name="section-3" id=
"section-3"></a>
<p class="First">KETEK tablets are available in two strengths:</p>
<ul class="Disc">
<li>Tablets: 400 mg supplied as light-orange, oval, film-coated
tablets, imprinted "H3647" on one side and "400" on the other
side.</li>
<li>Tablets: 300 mg supplied as light-orange, oval, film-coated
tablets, imprinted "38AV" on one side and blank on the other
side.</li>
</ul>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">4 CONTRAINDICATIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34070-3"><a name="S4" id="S4"></a> <a name="section-4" id=
"section-4"></a>
<div class="Section" data-sectioncode="42229-5"><a name="S4.1" id=
"S4.1"></a> <a name="section-4.1" id="section-4.1"></a>
<h2>4.1 Myasthenia Gravis</h2>
<p class="First">KETEK is contraindicated in patients with
myasthenia gravis. Exacerbations of myasthenia gravis have been
reported in patients and sometimes occurred within a few hours of
the first dose of KETEK. Reports have included fatal and
life-threatening acute respiratory failure with a rapid onset and
progression.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S4.2" id=
"S4.2"></a> <a name="section-4.2" id="section-4.2"></a>
<h2>4.2 Hepatitis</h2>
<p class="First">KETEK is contraindicated in patients with previous
history of hepatitis and/or jaundice associated with the use of
KETEK tablets, or any macrolide antibacterial. <span class=
"Italics">[see <a href="#S5.1">Warnings and Precautions
(5.1)</a>]</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S4.3" id=
"S4.3"></a> <a name="section-4.3" id="section-4.3"></a>
<h2>4.3 Hypersensitivity</h2>
<p class="First">KETEK is contraindicated in patients with a
history of hypersensitivity to telithromycin, any components of
KETEK tablets, or any macrolide antibacterial.<span class=
"Italics">[see <a href="#S11">Description (11)</a>]</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S4.4" id=
"S4.4"></a> <a name="section-4.4" id="section-4.4"></a>
<h2>4.4 Cisapride/Pimozide</h2>
<p class="First">Concomitant administration of KETEK with cisapride
or pimozide is contraindicated because co-administration can lead
to life-threatening QT prolongation. <span class="Italics">[see
<a href="#S5.2">Warnings and Precautions (5.2)</a>; <a href=
"#S7">Drug Interactions (7)</a>]</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S4.5" id=
"S4.5"></a> <a name="section-4.5" id="section-4.5"></a>
<h2>4.5 Colchicine</h2>
<p class="First">Concomitant administration of KETEK and colchicine
is contraindicated in patients with renal or hepatic impairment due
to increased plasma concentration of colchicine leading to
life-threatening colchicine toxicity. <span class="Italics">[see
<a href="#S5.4">Warnings and Precautions (5.4)</a>; <a href=
"#S7">Drug Interactions (7)</a>]</span></p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">5 WARNINGS AND PRECAUTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"43685-7"><a name="S5" id="S5"></a> <a name="section-5" id=
"section-5"></a>
<div class="Section" data-sectioncode="42229-5"><a name="S5.1" id=
"S5.1"></a> <a name="section-5.1" id="section-5.1"></a>
<h2>5.1 Hepatotoxicity</h2>
<p class="First">Acute hepatic failure and severe liver injury, in
some cases fatal, have been reported in patients treated with
KETEK. These hepatic reactions included fulminant hepatitis and
hepatic necrosis leading to liver transplant, and were observed
during or immediately after treatment. In some of these cases,
liver injury progressed rapidly and occurred after administration
of a few doses of KETEK<span class="Italics">.</span></p>
<p>Physicians and patients should monitor for the appearance of
signs or symptoms of hepatitis, such as fatigue, malaise, anorexia,
nausea, jaundice, bilirubinuria, alcoholic stools, liver
tenderness, or hepatomegaly. Patients with signs or symptoms of
hepatitis must be advised to discontinue KETEK and immediately seek
medical evaluation, which should include liver function
tests<span class="Italics">.</span> If clinical hepatitis or
transaminase elevations combined with other systemic symptoms
occur, KETEK should be permanently discontinued.</p>
<p>KETEK is contraindicated in patients with a previous history of
hepatitis and/or jaundice associated with the use of KETEK tablets,
or any macrolide antibacterial. <span class="Italics">[see <a href=
"#S4.2">Contraindications (4.2)</a>]</span></p>
<p>In addition, less severe hepatic dysfunction associated with
increased liver enzymes, hepatitis and in some cases jaundice was
reported with the use of KETEK. These events associated with less
severe forms of liver toxicity were reversible.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S5.2" id=
"S5.2"></a> <a name="section-5.2" id="section-5.2"></a>
<h2>5.2 QTc Prolongation</h2>
<p class="First" style="border-left:1px solid;"><span class=
"XmChange">KETEK can prolong the QTc interval of the
electrocardiogram in some patients leading to an increased risk for
ventricular arrhythmias, including ventricular tachycardia and
torsades de pointes with fatal outcomes. Thus, KETEK should be
avoided in patients with congenital prolongation of the QTc
interval, and in patients with ongoing proarrhythmic conditions
such as uncorrected hypokalemia or hypomagnesemia, clinically
significant bradycardia, and in patients receiving Class IA (e.g.,
quinidine and procainamide) or Class III (e.g., dofetilide)
antiarrhythmic agents.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Cases of
ventricular arrhythmias (including ventricular tachycardia and
torsades de pointes) have been reported post-marketing with KETEK
and sometimes occurred within a few hours of the first
dose<span class="Italics">.</span> In clinical trials, no
cardiovascular morbidity or mortality attributable to QTc
prolongation occurred with KETEK treatment in 4780 patients,
including 204 patients having a prolonged QTc at
baseline.</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S5.3" id=
"S5.3"></a> <a name="section-5.3" id="section-5.3"></a>
<h2>5.3 Visual Disturbances and Loss of Consciousness</h2>
<p class="First">KETEK may cause visual disturbances particularly
in slowing the ability to accommodate and the ability to release
accommodation. Visual disturbances, some of them severe, included
blurred vision, difficulty focusing, and diplopia. <span class=
"Italics">[see <a href="#S6.1">Adverse Reactions
(6.1)</a>]</span></p>
<p>There have been post-marketing reports of transient loss of
consciousness including some cases associated with vagal
syndrome<span class="Italics">.</span></p>
<p>Because of potential visual difficulties or loss of
consciousness, patients should attempt to minimize activities such
as driving a motor vehicle, operating heavy machinery or engaging
in other hazardous activities during treatment with KETEK. If
patients experience visual disorders or loss of consciousness while
taking KETEK, patients should not drive a motor vehicle, operate
heavy machinery or engage in other hazardous activities<span class=
"Italics">.</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S5.4" id=
"S5.4"></a> <a name="section-5.4" id="section-5.4"></a>
<h2>5.4 Serious Adverse Reactions with Concomitant Drugs</h2>
<p class="First">Serious adverse reactions have been reported in
patients taking KETEK concomitantly with CYP3A4 substrates
<span class="Italics">[see <a href="#S7">Drug Interactions
(7)</a>]</span>:</p>
<ul class="Disc">
<li>Colchicine: colchicine toxicity</li>
<li>Simvastatin, lovastatin, and atorvastatin: rhabdomyolysis</li>
<li>Calcium channel blockers metabolized by CYP3A4 (e.g.,
verapamil, amlodipine, diltiazem): hypotension</li>
</ul>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-5.4.1" id="section-5.4.1"></a>
<p class="First"><span class="Underline">Colchicine
Toxicity</span></p>
<p>Life-threatening and fatal drug interactions have been reported
in patients treated with colchicine and strong CYP3A4 inhibitors.
KETEK is a strong CYP3A4 inhibitor and this interaction may occur
while using both drugs at their recommended dosages. If
co-administration of KETEK and colchicine is necessary in patients
with normal renal and hepatic function, reduce the dosage of
colchicine. Monitor patients for clinical symptoms of colchicine
toxicity. Concomitant administration of KETEK and colchicine is
contraindicated in patients with renal or hepatic impairment.
<span class="Italics">[see <a href="#S4.5">Contraindications
(4.5)</a>; <a href="#S7">Drug Interactions (7)</a>]</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-5.4.2" id="section-5.4.2"></a>
<p class="First"><span class="Underline">Rhabdomyolysis</span></p>
<p>Simvastatin, lovastatin and atorvastatin are metabolized by
CYP3A4. High levels of HMG-CoA reductase inhibitors increase the
risk of myopathy and rhabdomyolysis. Avoid use of statins which are
metabolized by CYP3A4 concomitantly with KETEK; suspend therapy
with simvastatin, lovastatin, or atorvastatin during the course of
treatment with KETEK. <span class="Italics">[see <a href="#S7">Drug
Interactions (7)</a>]</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-5.4.3" id="section-5.4.3"></a>
<p class="First"><span class="Underline">Hypotension</span></p>
<p>Hypotension, bradyarrhythmia and loss of consciousness have been
observed in patients receiving concomitant treatment with calcium
channel blockers that are substrates of CYP3A4 (e.g., verapamil,
amlodipine, diltiazem). Monitor for these adverse reactions and
toxicity related to calcium channel blockers and adjust calcium
channel blocker dosage as necessary. <span class="Italics">[see
<a href="#S7">Drug Interactions (7)</a>]</span></p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S5.5" id=
"S5.5"></a> <a name="section-5.5" id="section-5.5"></a>
<h2>5.5 <span class="Italics">Clostridum
difficile</span>-Associated Diarrhea</h2>
<p class="First"><span class="Italics">Clostridium difficile</span>
associated diarrhea (CDAD) has been reported with use of nearly all
antibacterial agents, including KETEK, and may range in severity
from mild diarrhea to fatal colitis. Treatment with antibacterial
agents alters the normal flora of the colon leading to overgrowth
of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile</span> produces toxins A and
B which contribute to the development of CDAD. Hypertoxin producing
strains of <span class="Italics">C. difficile</span> cause
increased morbidity and mortality, as these infections can be
refractory to antimicrobial therapy and may require colectomy. CDAD
must be considered in all patients who present with diarrhea
following antibacterial use. Careful medical history is necessary
since CDAD has been reported to occur over two months after the
administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibacterial use not
directed against <span class="Italics">C. difficile</span> may need
to be discontinued. Appropriate fluid and electrolyte management,
protein supplementation, antibacterial treatment of <span class=
"Italics">C. difficile,</span> and surgical evaluation should be
instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S5.6" id=
"S5.6"></a> <a name="section-5.6" id="section-5.6"></a>
<h2>5.6 Development of Drug Resistant Bacteria</h2>
<p class="First">Prescribing KETEK in the absence of a proven or
strongly suspected bacterial infection is unlikely to provide
benefit to the patient and increases the risk of the development of
drug-resistant bacteria.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">6 ADVERSE REACTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34084-4"><a name="S6" id="S6"></a> <a name="section-6" id=
"section-6"></a>
<p class="First">The following serious and otherwise important
adverse drug reactions are discussed in greater detail in other
sections of labeling:</p>
<ul class="Disc">
<li>Myasthenia gravis <span class="Italics">[see <a href=
"#S4.1">Contraindications (4.1)</a>]</span></li>
<li>Hepatotoxicity <span class="Italics">[see <a href=
"#S5.1">Warnings and Precautions (5.1)</a>]</span></li>
<li>QTc prolongation <span class="Italics">[see <a href=
"#S5.2">Warnings and Precautions (5.2)</a>]</span></li>
<li>Visual disturbances and loss of consciousness <span class=
"Italics">[see <a href="#S5.3">Warnings and Precautions
(5.3)</a>]</span></li>
<li><span class="Italics">Clostridium difficile</span>-associated
diarrhea <span class="Italics">[see <a href="#S5.5">Warnings and
Precautions (5.5)</a>]</span></li>
</ul>
<div class="Section" data-sectioncode="42229-5"><a name="S6.1" id=
"S6.1"></a> <a name="section-6.1" id="section-6.1"></a>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely
varying conditions, adverse reaction rates observed in the clinical
trials of a drug cannot be directly compared to rates in the
clinical trials of another drug and may not reflect the rates
observed in practice.</p>
<p>In Phase 3 clinical trials, 4,780 patients (n=2702 in controlled
trials) received oral dosages of KETEK 800 mg once daily for 5 days
or 7 to 10 days. Note that treatment with KETEK for 5 days duration
is not a recommended dosage regimen. <span class="Italics">[see
<a href="#S2.1">Dosage and Administration (2.1)</a>]</span></p>
<p>In the combined Phase 3 studies, discontinuation due to adverse
reactions occurred in 4.4% of KETEK-treated patients and 4.3% of
combined comparator-treated patients. Most discontinuations in the
KETEK group were due to adverse reactions in the gastrointestinal
body system, primarily diarrhea (0.9% for KETEK vs. 0.7% for
comparators), and nausea (0.7% for KETEK vs. 0.5% for
comparators).</p>
<p>Adverse reactions (ARs) occurring in clinical studies in 2% or
more of KETEK patients are included below.</p>
<a name="table1" id="table1"></a>
<div class="scrollingtable">
<table width="75%">
<caption><span>Table 1. Adverse Reactions Reported in 2% or more of
Patients in Controlled Phase 3 Clinical Studies</span></caption>
<colgroup>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%"></colgroup>
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left">Adverse Reaction<a class="Sup"
href="#footnote-2" name="footnote-reference-2" id=
"footnote-reference-2">*</a></th>
<th class="Rrule" align="center" colspan="2">Percent Incidence</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">KETEK<br>
n= 2702</th>
<th class="Rrule" align="center">Comparator<a class="Sup" href=
"#footnote-3" name="footnote-reference-3" id=
"footnote-reference-3">†</a><br>
n= 2139</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<dl class="Footnote">
<dt><a href="#footnote-reference-2" name="footnote-2" id=
"footnote-2">*</a></dt>
<dd>Based on a frequency of all and possibly related adverse
reactions of 2% or more in KETEK or comparator groups.</dd>
<dt><a href="#footnote-reference-3" name="footnote-3" id=
"footnote-3">†</a></dt>
<dd>Includes comparators from all controlled Phase 3 studies.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Diarrhea</td>
<td class="Rrule" align="center">10%</td>
<td class="Rrule" align="center">8%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Nausea</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">4.1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Dizziness (excl. vertigo)</td>
<td class="Rrule" align="center">2.8%</td>
<td class="Rrule" align="center">1.5%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Vomiting</td>
<td class="Rrule" align="center">2.4%</td>
<td class="Rrule" align="center">1.4%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-6.1.1" id="section-6.1.1"></a>
<p class="First"><span class="Underline">Less Common Adverse
Reactions</span></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-6.1.1.1" id="section-6.1.1.1"></a>
<p class="First"><span class="Italics Underline">Frequency of 0.2%
or more and less than 2%</span></p>
<p>The following adverse reactions were observed at a frequency of
0.2% or more and less than 2% in KETEK-treated patients in clinical
studies.</p>
<dl>
<dd><span class="Italics">Gastrointestinal system:</span> abdominal
distension, dyspepsia, gastrointestinal upset, flatulence,
constipation, gastroenteritis, gastritis, anorexia, oral
candidiasis, glossitis, stomatitis.</dd>
</dl>
<dl>
<dd><span class="Italics">Liver and biliary system:</span> abnormal
liver function tests: increased transaminases (i.e., ALT, AST).
Hepatitis, with or without jaundice, occurred in 0.07% of patients
treated with KETEK. <span class="Italics">[see <a href=
"#S5.1">Warnings and Precautions (5.1)</a>]</span></dd>
</dl>
<dl>
<dd><span class="Italics">Nervous system:</span> dry mouth,
somnolence, insomnia, vertigo, increased sweating</dd>
</dl>
<dl>
<dd><span class="Italics">Body as a whole:</span> abdominal pain,
fatigue</dd>
</dl>
<dl>
<dd><span class="Italics">Special senses:</span> Visual adverse
reactions, some of them severe, most often included blurred vision,
diplopia, or difficulty focusing. Some patients discontinued
therapy due to these adverse reactions. Visual adverse reactions
were reported as having occurred after any dose during treatment,
but most (65%) occurred following the first or second dose. Visual
adverse reactions lasted several hours and recurred upon subsequent
dosing in some patients. For patients who continued treatment, some
visual adverse reactions resolved on therapy while others persisted
through the full course of treatment. <span class="Italics">[see
<a href="#S5.3">Warnings and Precautions (5.3)</a>]</span><br>
<br>
Females and patients under 40 years old experienced a higher
incidence of KETEK-associated visual adverse reactions. Table 2
provides the incidence of all visual adverse reactions in
controlled Phase 3 studies by age and gender. The group with the
highest incidence was females under the age of 40, while males over
the age of 40 had rates of visual adverse reactions similar to
comparator-treated patients.</dd>
</dl>
<a name="table2" id="table2"></a>
<div class="scrollingtable">
<table width="75%">
<caption><span>Table 2. Incidence of All Visual Adverse Reactions
in Controlled Phase 3 Studies</span></caption>
<colgroup>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="37%"></colgroup>
<thead>
<tr class="First Last">
<th class="Lrule Rrule" align="left">Gender/Age</th>
<th class="Rrule" align="center">Telithromycin</th>
<th class="Rrule" align="center">Comparators<a class="Sup" href=
"#footnote-4" name="footnote-reference-4" id=
"footnote-reference-4">*</a></th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<dl class="Footnote">
<dt><a href="#footnote-reference-4" name="footnote-4" id=
"footnote-4">*</a></dt>
<dd>Includes all comparators combined</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Female<br>
40 and under</span></td>
<td class="Rrule" align="center">2.1%<br>
(14/682)</td>
<td class="Rrule" align="center">0.0%<br>
(0/534)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Female<br>
greater than 40</span></td>
<td class="Rrule" align="center">1.0%<br>
(7/703)</td>
<td class="Rrule" align="center">0.35%<br>
(2/574)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Male<br>
40 and under</span></td>
<td class="Rrule" align="center">1.2%<br>
(7/563)</td>
<td class="Rrule" align="center">0.48%<br>
(2/417)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Male<br>
greater than 40</span></td>
<td class="Rrule" align="center">0.27%<br>
(2/754)</td>
<td class="Rrule" align="center">0.33%<br>
(2/614)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class=
"Bold">Total</span></td>
<td class="Rrule" align="center">1.1%<br>
(30/2702)</td>
<td class="Rrule" align="center">0.28%<br>
(6/2139)</td>
</tr>
</tbody>
</table>
</div>
<dl>
<dd><span class="Italics">Urogenital system:</span> vaginal
candidiasis, vaginitis, vaginosis fungal</dd>
</dl>
<dl>
<dd><span class="Italics">Skin:</span> rash</dd>
</dl>
<dl>
<dd><span class="Italics">Hematologic:</span> increased platelet
count</dd>
</dl>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-6.1.1.2" id="section-6.1.1.2"></a>
<p class="First"><span class="Italics Underline">Frequency of less
than 0.2%</span></p>
<p>Other clinically-significant adverse reactions occurring in less
than 0.2% of patients treated with KETEK from the controlled Phase
3 studies included: anxiety, bradycardia, eczema, elevated blood
bilirubin, erythema multiforme, flushing, hypotension, increased
blood alkaline phosphatase, increased eosinophil count,
paresthesia, pruritus, urticaria.</p>
</div>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S6.2" id=
"S6.2"></a> <a name="section-6.2" id="section-6.2"></a>
<h2>6.2 Post-Marketing Experience</h2>
<p class="First">The following adverse reactions have been
identified during post-approval use of KETEK. Because these
reactions are reported voluntarily from a population of uncertain
size, it is not always possible to reliably estimate their
frequency or establish a causal relationship to drug exposure.</p>
<dl>
<dd><span class="Italics">Allergic:</span> face edema, severe
allergic (hypersensitivity) reactions, including angioedema and
anaphylaxis</dd>
</dl>
<dl>
<dd><span class="Italics">Cardiovascular:</span> atrial
arrhythmias, ventricular arrhythmias (including ventricular
tachycardia and torsades de pointes) with potential fatal outcome,
palpitation, ischemic cardiac events in the context of
hypersensitivity reactions <span class="Italics">[see <a href=
"#S5.2">Warnings and Precautions (5.2)</a>]</span></dd>
</dl>
<dl>
<dd><span class="Italics">Gastrointestinal system:</span>
pseudomembranous colitis, pancreatitis <span class="Italics">[see
<a href="#S5.5">Warnings and Precautions (5.5</a>]</span></dd>
</dl>
<dl>
<dd><span class="Italics">Liver and biliary system:</span> Hepatic
dysfunction, fulminant hepatitis, hepatic necrosis, and hepatic
failure, chromaturia <span class="Italics">[see <a href=
"#S4.2">Contraindications (4.2)</a>; <a href="#S5.1">Warnings and
Precautions (5.1)</a>]</span></dd>
</dl>
<dl>
<dd><span class="Italics">Musculoskeletal:</span> muscle cramps,
arthralgia, myalgia, exacerbation of myasthenia gravis <span class=
"Italics">[see <a href="#S4.1">Contraindications
(4.1)</a>]</span></dd>
</dl>
<dl>
<dd><span class="Italics">Nervous system:</span> loss of
consciousness, in some cases associated with vagal syndrome,
tremor, convulsions</dd>
</dl>
<dl>
<dd><span class="Italics">Psychiatric disorders:</span> confusion,
hallucinations (mostly visual)</dd>
</dl>
<dl>
<dd><span class="Italics">Special senses:</span> taste/smell
perversion and/or loss, hearing loss</dd>
</dl>
<dl>
<dd><span class="Italics">Respiratory, thoracic and mediastinal
disorders:</span> dyspnea</dd>
</dl>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">7 DRUG INTERACTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34073-7"><a name="S7" id="S7"></a> <a name="section-7" id=
"section-7"></a>
<p class="First">Telithromycin is a strong inhibitor of CYP3A4 and
also a CYP3A4 substrate. Co-administration of KETEK and drugs that
induce or inhibit the cytochrome P450 3A4 enzyme system may affect
KETEK plasma concentrations resulting in diminished efficacy or an
increase or prolongation of both the therapeutic and adverse
effects; therefore, appropriate dosage adjustments may be necessary
for drugs co-administered with telithromycin.</p>
<p>Studies were performed to evaluate the effect of CYP3A4
inhibitors on telithromycin and the effect of telithromycin on
drugs that are substrates of CYP3A4 and CYP2D6. In addition, drug
interaction studies were conducted with several other concomitantly
prescribed drugs. Table 3 summarizes both drugs with
pharmacokinetics that are affected by KETEK as well as drugs that
affect the pharmacokinetics of KETEK.</p>
<a name="table3" id="table3"></a>
<div class="scrollingtable">
<table width="95%">
<caption><span>Table 3: Clinically Significant Drug Interactions
with KETEK</span></caption>
<colgroup>
<col align="left" valign="top" width="38%">
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="32%"></colgroup>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" colspan="3"><span class=
"Bold">Drugs That Are Affected By KETEK</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">Drug(s)
with Pharmacokinetics Affected by KETEK<br>
(Mechanism of interaction, if known)</span></td>
<td class="Rrule" align="center"><span class=
"Bold">Recommendation<br>
(Exposure)</span></td>
<td class="Rrule" align="center"><span class=
"Bold">Comments</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class=
"Bold">Cisapride<br>
(CYP3A4 Substrate)</span></td>
<td class="Rrule" align="left"><span class=
"Bold">Contraindicated<br>
(Plasma exposure increased)</span></td>
<td class="Rrule" align="left">Co-administration of cisapride with
repeated doses of KETEK resulted in significant increases in QTc.
<span class="Italics">[see <a href="#S4.4">Contraindications
(4.4)</a>]</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class=
"Bold">Pimozide<br>
(CYP3A4 Substrate)</span></td>
<td class="Rrule" align="left"><span class=
"Bold">Contraindicated<br>
(Plasma exposure likely to be increased)</span></td>
<td class="Rrule" align="left">Although there are no studies
looking at the interaction between KETEK and pimozide, there is a
potential risk of life-threatening QT prolongation. <span class=
"Italics">[see <a href="#S4.4">Contraindications
(4.4)</a>]</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class=
"Bold">Colchicine</span><br>
<br>
<br>
<span class="Bold">(CYP3A4 and P-glycoprotein efflux transporter
Substrate)</span></td>
<td class="Rrule" align="left"><span class=
"Bold">Contraindicated</span> in patients with renal or hepatic
impairment.<br>
<br>
<span class="Bold">(Plasma exposure increased)</span></td>
<td class="Rrule" align="left">Risk of life-threatening colchicine
toxicity. If co-administration of KETEK and colchicine is necessary
in patients with normal renal and hepatic function, reduce the dose
of colchicine. Monitor for symptoms of colchicine toxicity.
<span class="Italics">[see <a href="#S4.5">Contraindications
(4.5)</a>; <a href="#S5.5">Warnings and Precautions
(5.5)</a>]</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class=
"Bold">Simvastatin, Lovastatin, and Atorvastatin (HMG-CoA Reductase
Inhibitors metabolized by CYP3A4)<br>
(CYP3A4 Substrate)</span></td>
<td class="Rrule" align="left"><span class="Bold">Avoid Use<br>
(Plasma exposure increased)</span></td>
<td class="Rrule" align="left">High levels of HMG-CoA reductase
inhibitors increase the risk of myopathy and rhabdomyolysis. Avoid
concomitant use of simvastatin, lovastatin, or atorvastatin with
KETEK. If KETEK is prescribed, suspend therapy with simvastatin,
lovastatin, or atorvastatin during the course of KETEK. An
interaction may occur with simvastatin, lovastatin or atorvastatin
but not with statins which are not metabolized by CYP3A4.
<span class="Italics">[see <a href="#S5.5">Warnings and Precautions
(5.5)</a>]</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Ergot
Alkaloids</span><br></td>
<td class="Rrule" align="left"><span class="Bold">Not
Recommended<br>
(Plasma exposure likely to be increased)</span></td>
<td class="Rrule" align="left">No specific drug interaction studies
have been performed. However, acute ergot toxicity characterized by
severe peripheral vasospasm and dysesthesia has been reported when
macrolide antibiotics were co-administered with ergot alkaloid
derivatives (such as ergotamine or dihydroergotamine). Without
further data, the co-administration of KETEK and these drugs is not
recommended.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Calcium
Channel Blockers<br>
(CYP3A4 Substrate)</span><br></td>
<td class="Rrule" align="left"><span class="Bold">Use with
Caution<br>
(Plasma exposure increased)</span></td>
<td class="Rrule" align="left">Hypotension, bradyarrhythmia, and
loss of consciousness have been observed in patients receiving
concomitant treatment with calcium channel blockers that are
substrates of CYP3A4 (e.g., verapamil, amlodipine, diltiazem).
Monitor for these adverse reactions and toxicity related to calcium
channel blockers and adjust calcium channel blocker dosage as
necessary.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class=
"Bold">Midazolam<br>
(CYP3A4 Substrate)</span><br></td>
<td class="Rrule" align="left"><span class="Bold">Use with
Caution<br>
(Plasma exposure likely to be increased)</span></td>
<td class="Rrule" align="left">Monitor for benzodiazepine-related
adverse reactions and adjust midazolam dosage if necessary. Use
caution with other benzodiazepines, which are metabolized by CYP3A4
and undergo a high first-pass effect (e.g., triazolam).</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Other drugs
metabolized by CYP3A4, such as carbamazepine, cyclosporine,
tacrolimus, sirolimus, hexobarbital, and phenytoin</span><br>
<span class="Bold">(CYP3A4 Substrates)</span></td>
<td class="Rrule" align="left"><span class="Bold">Use with
Caution<br>
(Plasma exposure likely to be increased)</span></td>
<td class="Rrule" align="left">No specific drug interaction studies
have been performed to evaluate these drug-drug interactions with
KETEK. However, increases or prolongation of the therapeutic and/or
adverse effects of drugs metabolized by the cytochrome P450 system
may be observed if administered with KETEK.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class=
"Bold">Metoprolol<br>
(CYP2D6 Substrate)</span></td>
<td class="Rrule" align="left"><span class="Bold">Use with
Caution<br>
(Plasma exposure increased)</span></td>
<td class="Rrule" align="left">Co-administration of KETEK and
metoprolol in patients with heart failure could lead to metoprolol
toxicity and should be considered with caution. Monitor for
metoprolol toxicity and adjust metoprolol dosage.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class=
"Bold">Digoxin</span></td>
<td class="Rrule" align="left"><span class="Bold">Use with
Caution<br>
(Plasma exposure increased)</span></td>
<td class="Rrule" align="left">Monitor for digoxin side effects or
serum levels during concomitant administration of digoxin and
KETEK.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class=
"Bold">Theophylline</span><br></td>
<td class="Rrule" align="left"><span class="Bold">Use with
Caution<br>
(Plasma exposure minimally increased)</span></td>
<td class="Rrule" align="left">Co-administration of theophylline
may worsen gastrointestinal effects such as nausea and vomiting,
especially in female patients. Administer theophylline and KETEK 1
hour apart to decrease the likelihood of gastrointestinal side
effects.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Oral
Anticoagulants</span></td>
<td class="Rrule" align="left"><span class="Bold">Use with
Caution<br>
(Plasma exposure increased)</span></td>
<td class="Rrule" align="left">Spontaneous post-marketing reports
suggest that administration of KETEK and oral anticoagulants
concomitantly may potentiate the effects of the oral
anticoagulants. Consider monitoring prothrombin times/INR while
patients are receiving KETEK and oral anticoagulants
simultaneously.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" colspan="3"><span class=
"Bold">Drugs that Affect KETEK</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">Drug(s)
that Affect the Pharmacokinetics of KETEK</span></td>
<td class="Rrule" align="center"><span class=
"Bold">Recommendation</span></td>
<td class="Rrule" align="center"><span class=
"Bold">Comments</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class=
"Bold">Rifampin<br>
(CYP3A4 Inducer)</span></td>
<td class="Rrule" align="left"><span class="Bold">Avoid Concomitant
Use<br>
(Reduced KETEK exposure)</span></td>
<td class="Rrule" align="left">Loss of KETEK effect is likely
[<span class="Italics">see <a href="#S12.3">Clinical Pharmacology
(12.3)</a></span>]</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Other
CYP3A4 inducers (phenytoin, carbamazepine, or
phenobarbital)</span></td>
<td class="Rrule" align="left"><span class="Bold">Avoid Concomitant
Use<br>
(Reduced KETEK exposure)</span></td>
<td class="Rrule" align="left">Loss of KETEK effect is likely
[<span class="Italics">see <a href="#S12.3">Clinical Pharmacology
(12.3)</a></span>]</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class=
"Bold">Itraconazole and Ketoconazole</span><br></td>
<td class="Rrule" align="left"><span class="Bold">Avoid Concomitant
Use<br>
(Increased KETEK exposure)</span></td>
<td class="Rrule" align="left">Increased KETEK toxicity is likely
[<span class="Italics">see <a href="#S12.3">Clinical Pharmacology
(12.3)</a></span>]</td>
</tr>
</tbody>
</table>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">8 USE IN SPECIFIC POPULATIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"43684-0"><a name="S8" id="S8"></a> <a name="section-8" id=
"section-8"></a>
<div class="Section" data-sectioncode="42228-7"><a name="S8.1" id=
"S8.1"></a> <a name="section-8.1" id="section-8.1"></a>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectioncode="34077-8"><a name=
"section-8.1.1" id="section-8.1.1"></a>
<p class="First">Pregnancy Category C.</p>
<p>There are no adequate and well-controlled studies in pregnant
women. Telithromycin should be used during pregnancy only if the
potential benefit justifies the potential risk to the fetus.</p>
<p>Telithromycin was not teratogenic in the rat or rabbit.
Reproduction studies have been performed in rats and rabbits, with
effect on pre-post natal development studied in the rat. At doses
of 150 and 20 mg/kg/day in rats and rabbits respectively
(approximately 2 and 0.5 times the recommended clinical dose), no
evidence of fetal terata was found. At doses higher than 150 or 20
mg/kg in rats and rabbits, respectively, maternal toxicity may have
resulted in delayed fetal maturation. No adverse effects on
prenatal and postnatal development of rat pups were observed at 125
mg/kg/day (1.5 times) the daily human dose.</p>
</div>
</div>
<div class="Section" data-sectioncode="34080-2"><a name="S8.3" id=
"S8.3"></a> <a name="section-8.2" id="section-8.2"></a>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Telithromycin is excreted in breast milk of rats.
Telithromycin may also be excreted in human milk. Because many
drugs are excreted in human milk, caution should be exercised when
KETEK is administered to a nursing mother.</p>
</div>
<div class="Section" data-sectioncode="34081-0"><a name="S8.4" id=
"S8.4"></a> <a name="section-8.3" id="section-8.3"></a>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of KETEK in pediatric
patients less than18 years of age has not been established.
Pediatric clinical trials were halted prematurely due to concern of
serious postmarketing hepatic adverse reactions observed in adults.
<span class="Italics">[see <a href="#S5.1">Warnings and Precautions
(5.1)</a>]</span></p>
</div>
<div class="Section" data-sectioncode="34082-8"><a name="S8.5" id=
"S8.5"></a> <a name="section-8.4" id="section-8.4"></a>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of patients in Phase 3
clinical trials (n=4,780), KETEK was administered to 694 patients
who were 65 years and older, including 231 patients who were 75
years and older. Efficacy and safety in patients 65 years and older
were generally similar to that observed in younger patients;
however, greater sensitivity of some older individuals cannot be
ruled out. <span class="Italics">[see <a href="#S12.3">Clinical
Pharmacology (12.3)</a>]</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S8.6" id=
"S8.6"></a> <a name="section-8.5" id="section-8.5"></a>
<h2>8.6 Renal and/or Hepatic Impairment</h2>
<p class="First">Dose adjustment is required in patients with
severe renal impairment (CL<span class="Sub">Cr</span> less than 30
mL/min) or on dialysis. Further dose adjustment is required in
patients with severe renal impairment and coexisting hepatic
impairment. [<span class="Italics">see <a href="#S2.2">Dosage and
Administration (2.2)</a></span>]</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">10 OVERDOSAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34088-5"><a name="S10" id="S10"></a> <a name="section-9" id=
"section-9"></a>
<p class="First">In the event of acute overdosage, the stomach
should be emptied by gastric lavage. The patient should be
carefully monitored (e.g., ECG, electrolytes) and given symptomatic
and supportive treatment. Adequate hydration should be maintained.
The effectiveness of hemodialysis in an overdose situation with
KETEK is unknown.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">11 DESCRIPTION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34089-3"><a name="S11" id="S11"></a> <a name="section-10" id=
"section-10"></a>
<p class="First">KETEK tablets contain telithromycin, a
semisynthetic antibacterial in the ketolide class for oral
administration. Chemically, telithromycin is designated as
Erythromycin,
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]-.</p>
<p>Telithromycin, a ketolide, differs chemically from the macrolide
group of antibacterials by the lack of α-L-cladinose at position 3
of the erythronolide A ring, resulting in a 3-keto function. It is
further characterized by a C11-12 carbamate substituted by an
imidazolyl and pyridyl ring through a butyl chain. Its empirical
formula is C<span class="Sub">43</span>H<span class=
"Sub">65</span>N<span class="Sub">5</span>O<span class=
"Sub">10</span> and its molecular weight is 812.03. Telithromycin
is a white to off-white crystalline powder. The following
represents the chemical structure of telithromycin.</p>
<p><img src=
"image.cfm?setid=4471223e-9023-457e-be2e-8e4e0c2d94d1&amp;name=ketek-01.jpg"
alt="Chemical Structure"></p>
<p>KETEK tablets are available as light-orange, oval, film-coated
tablets, each containing 400 mg or 300 mg of telithromycin, and the
following inactive ingredients: croscarmellose sodium,
hypromellose, magnesium stearate, microcrystalline cellulose,
polyethylene glycol, povidone, red ferric oxide, talc, titanium
dioxide, and yellow ferric oxide.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">12 CLINICAL PHARMACOLOGY</a>
<div class="Section toggle-content closed" data-sectioncode=
"34090-1"><a name="S12" id="S12"></a> <a name="section-11" id=
"section-11"></a>
<div class="Section" data-sectioncode="43679-0"><a name="S12.1" id=
"S12.1"></a> <a name="section-11.1" id="section-11.1"></a>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Telithromycin is a ketolide antibacterial drug.
<span class="Italics">[see <a href="#S12.4">Clinical Pharmacology
(12.4)</a>]</span></p>
</div>
<div class="Section" data-sectioncode="43682-4"><a name="S12.3" id=
"S12.3"></a> <a name="section-11.2" id="section-11.2"></a>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of telithromycin after
administration of single and multiple (7 days) once daily 800-mg
doses to healthy adult subjects are shown in Table 4.</p>
<a name="table4" id="table4"></a>
<div class="scrollingtable">
<table width="75%">
<caption><span>Table 4: Pharmacokinetics of Telithromycin in
Healthy Subjects</span></caption>
<colgroup>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%"></colgroup>
<thead>
<tr class="Botrule First">
<th align="left"></th>
<th align="center" colspan="2">Mean (SD)</th>
</tr>
<tr class="Last">
<th align="left">Parameter</th>
<th align="center">Single dose (n=18)</th>
<th align="center">Multiple dose (n=18)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last">
<td align="left" colspan="3">SD=Standard deviation ; C<span class=
"Sub">max</span>=Maximum plasma concentration ; T<span class=
"Sub">max</span>=Time to C<span class="Sub">max</span>; AUC=Area
under concentration vs. time curve; t<span class=
"Sub">1/2</span>=Terminal plasma half-life; C<span class=
"Sub">24h</span> =Plasma concentration at 24 hours post-dose</td>
</tr>
<tr>
<td align="left" colspan="3">
<dl class="Footnote">
<dt><a href="#footnote-reference-5" name="footnote-5" id=
"footnote-5">*</a></dt>
<dd>Median (min-max) values</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left">C<span class="Sub">max</span> (µg/mL)</td>
<td align="center">1.9 (0.80)</td>
<td align="center">2.27 (0.71)</td>
</tr>
<tr>
<td align="left">T<span class="Sub">max</span> (h)<a class="Sup"
href="#footnote-5" name="footnote-reference-5" id=
"footnote-reference-5">*</a></td>
<td align="center">1.0 (0.5–4.0)</td>
<td align="center">1.0 (0.5–3.0)</td>
</tr>
<tr>
<td align="left">AUC<span class="Sub">(0–24)</span> (µg∙h/mL)</td>
<td align="center">8.25 (2.6)</td>
<td align="center">12.5 (5.4)</td>
</tr>
<tr>
<td align="left">Terminal <span class="Sub">t1/2</span> (h)</td>
<td align="center">7.16 (1.3)</td>
<td align="center">9.81 (1.9)</td>
</tr>
<tr class="Last">
<td align="left">C<span class="Sub">24h</span> (µg/mL)</td>
<td align="center">0.03 (0.013)</td>
<td align="center">0.07 (0.051)</td>
</tr>
</tbody>
</table>
</div>
<p>In patients, mean peak and trough plasma concentrations were 2.9
µg/mL (±1.55), (n=219) and 0.2 µg/mL (±0.22), (n=204),
respectively, after 3 to 5 days of KETEK 800 mg once daily.
Steady-state plasma concentrations are reached within 2 to 3 days
of once daily dosing with KETEK 800 mg.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.1" id="section-11.2.1"></a>
<p class="First"><span class="Underline">Absorption</span></p>
<p>Following oral administration, telithromycin reached maximal
concentration at about 1 hour (0.5 – 4 hours). KETEK has an
absolute bioavailability of 57% in both young and elderly
subjects.</p>
<p>The rate and extent of absorption are unaffected by food intake,
thus KETEK tablets can be given without regard to food.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.2" id="section-11.2.2"></a>
<p class="First"><span class="Underline">Distribution</span></p>
<p>Total <span class="Italics">in vitro</span> protein binding is
approximately 60% to 70% and is primarily due to human serum
albumin.</p>
<p>Protein binding is not modified in elderly subjects or in
patients with hepatic impairment.</p>
<p>The volume of distribution of telithromycin after intravenous
infusion is 2.9 L/kg.</p>
<p>Telithromycin concentrations in bronchial mucosa, epithelial
lining fluid, and alveolar macrophages after 800 mg once daily
dosing for 5 days in patients are displayed in Table 5.</p>
<a name="table5" id="table5"></a>
<div class="scrollingtable">
<table width="80%">
<caption><span>Table 5</span></caption>
<colgroup>
<col align="left" valign="top" width="24%">
<col align="center" valign="top" width="19%">
<col align="center" valign="top" width="19%">
<col align="center" valign="top" width="19%">
<col align="center" valign="top" width="19%"></colgroup>
<thead>
<tr class="First">
<th align="left" rowspan="2"></th>
<th align="center" rowspan="2">Hours post-dose</th>
<th align="center" colspan="2">Mean concentration (µg/mL)</th>
<th align="center" rowspan="2">Tissue/Plasma Ratio</th>
</tr>
<tr class="Last">
<th align="center">Tissue or fluid</th>
<th align="center">Plasma</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="5">
<dl class="Footnote">
<dt><a href="#footnote-reference-6" name="footnote-6" id=
"footnote-6">*</a></dt>
<dd>Units in mg/kg</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left">Bronchial mucosa</td>
<td align="center">2</td>
<td align="center">3.88<a class="Sup" href="#footnote-6" name=
"footnote-reference-6" id="footnote-reference-6">*</a></td>
<td align="center">1.86</td>
<td align="center">2.11</td>
</tr>
<tr>
<td align="left"></td>
<td align="center">12</td>
<td align="center">1.41<a class="Sup" href="#footnote-6">*</a></td>
<td align="center">0.23</td>
<td align="center">6.33</td>
</tr>
<tr class="Botrule">
<td align="left"></td>
<td align="center">24</td>
<td align="center">0.78<a class="Sup" href="#footnote-6">*</a></td>
<td align="center">0.08</td>
<td align="center">12.11</td>
</tr>
<tr>
<td align="left">Epithelial lining fluid</td>
<td align="center">2</td>
<td align="center">14.89</td>
<td align="center">1.86</td>
<td align="center">8.57</td>
</tr>
<tr>
<td align="left"></td>
<td align="center">12</td>
<td align="center">3.27</td>
<td align="center">0.23</td>
<td align="center">13.8</td>
</tr>
<tr class="Botrule">
<td align="left"></td>
<td align="center">24</td>
<td align="center">0.84</td>
<td align="center">0.08</td>
<td align="center">14.41</td>
</tr>
<tr>
<td align="left">Alveolar macrophages</td>
<td align="center">2</td>
<td align="center">65</td>
<td align="center">1.07</td>
<td align="center">55</td>
</tr>
<tr>
<td align="left"></td>
<td align="center">8</td>
<td align="center">100</td>
<td align="center">0.605</td>
<td align="center">180</td>
</tr>
<tr class="Last">
<td align="left"></td>
<td align="center">24</td>
<td align="center">41</td>
<td align="center">0.073</td>
<td align="center">540</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.3" id="section-11.2.3"></a>
<p class="First"><span class="Underline">Metabolism</span></p>
<p>In total, approximately 70% of the telithromycin dose is
metabolized. In plasma, the main circulating compound after
administration of an 800-mg radio-labeled dose was parent compound,
representing 56.7% of the total radioactivity. The main metabolite
represented 12.6% of the AUC of telithromycin. Three other plasma
metabolites were quantified, each representing 3% or less of the
AUC of telithromycin.</p>
<p>It is estimated that approximately 50% of its metabolism is
mediated by CYP3A4 and the remaining 50% is CYP -independent.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.4" id="section-11.2.4"></a>
<p class="First"><span class="Underline">Excretion</span></p>
<p>The systemically available telithromycin is eliminated by
multiple pathways as follows: 7% of the dose is excreted unchanged
in feces by biliary and/or intestinal secretion; 13% of the dose is
excreted unchanged in urine by renal excretion; and 37% of the dose
is metabolized by the liver. Following oral dosing, the mean
terminal elimination half-life of telithromycin is 10 hours.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.5" id="section-11.2.5"></a>
<p class="First"><span class="Underline">Specific
Populations</span></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.5.1" id="section-11.2.5.1"></a>
<p class="First"><span class="Italics"><span class=
"Underline">Gender:</span></span> There was no significant
difference between males and females in mean AUC, C<span class=
"Sub">max</span>, and elimination half-life in two studies; one in
18 healthy young volunteers (18 to 40 years of age) and the other
in 14 healthy elderly volunteers (65 to 92 years of age), given
single and multiple once daily doses of 800 mg of KETEK.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.5.2" id="section-11.2.5.2"></a>
<p class="First"><span class="Italics Underline">Hepatic
impairment</span><span class="Italics">:</span> Telithromycin is
excreted via the liver and kidney. <span class="Italics">[see
<a href="#S2.2">Dosage and Administration (2.2)</a>]</span></p>
<p>In a single-dose study (800 mg) in 12 patients and a
multiple-dose study (800 mg) in 13 patients with mild to severe
hepatic insufficiency (Child Pugh Class A, B and C), the
C<span class="Sub">max</span>, AUC and t<span class=
"Sub">1/2</span> of telithromycin were similar to those obtained in
age- and sex-matched healthy subjects. In both studies, an increase
in renal elimination was observed in hepatically impaired patients
indicating that this pathway may compensate for some of the
decrease in metabolic clearance.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.5.3" id="section-11.2.5.3"></a>
<p class="First"><span class="Italics Underline">Renal
impairment</span><span class="Italics">:</span> Telithromycin is
excreted via the liver and kidney. <span class="Italics">[see
<a href="#S2.2">Dosage and Administration (2.2)</a>]</span></p>
<p>In a multiple-dose study, 36 subjects with varying degrees of
renal impairment received 400 mg, 600 mg, or 800 mg KETEK once
daily for 5 days. There was a 1.4-fold increase in C<span class=
"Sub">max,ss,</span> and a 1.9-fold increase in AUC
(0–24)<span class="Sub">ss</span> at 800 mg multiple doses in the
severely renally impaired group (CL<span class="Sub">CR</span> less
than 30 mL/min) compared to healthy volunteers. Renal excretion may
serve as a compensatory elimination pathway for telithromycin in
situations where metabolic clearance is impaired. Patients with
severe renal impairment are prone to conditions that may impair
their metabolic clearance.</p>
<p>In a single-dose study in patients with end-stage renal failure
on hemodialysis (n=10), the mean C<span class="Sub">max</span> and
AUC values were similar to normal healthy subjects when KETEK was
administered 2 hours post-dialysis. However, the effect of dialysis
on removing telithromycin from the body has not been studied.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.5.4" id="section-11.2.5.4"></a>
<p class="First"><span class="Italics Underline">Combined Renal and
Hepatic Impairment</span><span class="Italics">:</span> The effects
of co-administration of ketoconazole in 12 subjects (age 60 years
and older), with impaired renal function were studied
(CL<span class="Sub">CR</span>= 24 to 80 mL/min). In this study,
when severe renal insufficiency (CL<span class="Sub">CR</span> less
than 30 mL/min, n=2) and concomitant impairment of CYP3A4
metabolism pathway were present, telithromycin exposure
(AUC<span class="Sub">0–24</span>) was increased by approximately
4- to 5-fold compared with the exposure in healthy subjects with
normal renal function receiving telithromycin alone. In the
presence of severe renal impairment (CL<span class="Sub">CR</span>
less than 30 mL/min), with coexisting hepatic impairment, a reduced
dosage of KETEK is recommended. <span class="Italics">[see <a href=
"#S2.2">Dosage and Administration (2.2)</a>]</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.5.5" id="section-11.2.5.5"></a>
<p class="First"><span class="Italics">Geriatric:</span>
Pharmacokinetic data show that there is an increase of 1.4-fold in
exposure (AUC) in 20 patients 65 years and older with community
acquired pneumonia in a Phase 3 study, and a 2.0-fold increase in
exposure (AUC) in 14 subjects 65 years and older as compared with
subjects less than 65 years of age in a Phase I study. No dosage
adjustment is required based on age alone. <span class=
"Italics">[see <a href="#S8.5">Use in Specific Populations
(8.5)</a>]</span></p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.6" id="section-11.2.6"></a>
<p class="First"><span class="Underline">Drug
Interactions</span></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.6.1" id="section-11.2.6.1"></a>
<p class="First"><span class="Italics">CYP3A4 inducers</span></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.6.1.1" id="section-11.2.6.1.1"></a>
<p class="First"><span class="Italics"><span class=
"Underline">Rifampin</span></span></p>
<p>During concomitant administration of rifampin and KETEK in
repeated doses, C<span class="Sub">max</span> and AUC of
telithromycin were decreased by 79%, and 86%, respectively.
<span class="Italics">[see <a href="#S7">Drug Interactions
(7)</a>]</span></p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.6.2" id="section-11.2.6.2"></a>
<p class="First"><span class="Italics">CYP3A4 inhibitors</span></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.6.2.1" id="section-11.2.6.2.1"></a>
<p class="First"><span class="Italics"><span class=
"Underline">Itraconazole:</span></span> A multiple-dose interaction
study with itraconazole showed that C<span class="Sub">max</span>
of telithromycin was increased by 22% and AUC by 54%. <span class=
"Italics">[see <a href="#S7">Drug Interactions (7)</a>]</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.6.2.2" id="section-11.2.6.2.2"></a>
<p class="First"><span class="Italics"><span class=
"Underline">Ketoconazole:</span></span> A multiple-dose interaction
study with ketoconazole showed that C<span class="Sub">max</span>
of telithromycin was increased by 51% and AUC by 95%. <span class=
"Italics">[see <a href="#S7">Drug Interactions (7)</a>]</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.6.2.3" id="section-11.2.6.2.3"></a>
<p class="First"><span class="Italics"><span class=
"Underline">Grapefruit juice:</span></span> When telithromycin was
given with 240 mL of grapefruit juice after an overnight fast to
healthy subjects, the pharmacokinetics of telithromycin were not
affected.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.6.3" id="section-11.2.6.3"></a>
<p class="First"><span class="Italics">CYP3A4 substrates</span></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.6.3.1" id="section-11.2.6.3.1"></a>
<p class="First"><span class=
"Italics Underline">Simvastatin:</span> When simvastatin was
co-administered with telithromycin, there was a 5.3-fold increase
in simvastatin C<span class="Sub">max</span>, an 8.9-fold increase
in simvastatin AUC, a 15-fold increase in the simvastatin active
metabolite C<span class="Sub">max</span>, and a 12-fold increase in
the simvastatin active metabolite AUC. In another study, when
simvastatin and telithromycin were administered 12 hours apart,
there was a 3.4-fold increase in simvastatin C<span class=
"Sub">max</span>, a 4.0-fold increase in simvastatin AUC, a
3.2-fold increase in the active metabolite C<span class=
"Sub">max</span>, and a 4.3-fold increase in the active metabolite
AUC. <span class="Italics">[see <a href="#S5.4">Warnings and
Precautions (5.4)</a>; <a href="#S7">Drug Interactions
(7)</a>]</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.6.3.2" id="section-11.2.6.3.2"></a>
<p class="First"><span class="Italics">Midazolam:</span>
Concomitant administration of telithromycin with intravenous or
oral midazolam resulted in 2- and 6-fold increases, respectively,
in the AUC of midazolam due to inhibition of CYP3A4-dependent
metabolism of midazolam. <span class="Italics">[see <a href=
"#S7">Drug Interactions (7)</a>]</span></p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.6.4" id="section-11.2.6.4"></a>
<p class="First"><span class="Italics">Other Drugs</span></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.6.4.1" id="section-11.2.6.4.1"></a>
<p class="First"><span class="Italics Underline">Digoxin</span></p>
<p>The plasma peak and trough levels of digoxin were increased by
73% and 21%, respectively, in healthy volunteers when
co-administered with KETEK. However, trough plasma concentrations
of digoxin (when equilibrium between plasma and tissue
concentrations has been achieved) ranged from 0.74 to 2.17 ng/mL.
There were no significant changes in ECG parameters and no signs of
digoxin toxicity. <span class="Italics">[see <a href="#S7">Drug
Interactions (7)</a>]</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.6.4.2" id="section-11.2.6.4.2"></a>
<p class="First"><span class=
"Italics Underline">Theophylline</span></p>
<p>When theophylline was co-administered with repeated doses of
KETEK, there was an increase of approximately 16% and 17% on the
steady-state C<span class="Sub">max</span> and AUC of theophylline.
<span class="Italics">[see <a href="#S7">Drug Interactions
(7)</a>]</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.6.4.3" id="section-11.2.6.4.3"></a>
<p class="First"><span class="Italics Underline">Sotalol</span></p>
<p>KETEK has been shown to decrease the C<span class=
"Sub">max</span> and AUC of sotalol by 34% and 20%, respectively,
due to decreased absorption.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.6.4.4" id="section-11.2.6.4.4"></a>
<p class="First"><span class="Italics Underline">Oral
Contraceptives</span></p>
<p>When oral contraceptives containing ethinyl estradiol and
levonorgestrel were co-administered with KETEK, the steady-state
AUC of ethinyl estradiol did not change and the steady-state AUC of
levonorgestrel was increased by 50%. The
pharmacokinetic/pharmacodynamic study showed that telithromycin did
not interfere with the antiovulatory effect of oral contraceptives
containing ethinyl estradiol and levonorgestrel.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.6.4.5" id="section-11.2.6.4.5"></a>
<p class="First"><span class=
"Italics Underline">Metoprolol</span></p>
<p>When metoprolol was co-administered with KETEK, there was an
increase of approximately 38% on the C<span class="Sub">max</span>
and AUC of metoprolol; however, there was no effect on the
elimination half-life of metoprolol. Telithromycin exposure is not
modified with concomitant single-dose administration of metoprolol.
<span class="Italics">[see <a href="#S7">Drug Interactions
(7)</a>]</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.6.4.6" id="section-11.2.6.4.6"></a>
<p class="First"><span class=
"Italics Underline">Ranitidine/Antacid</span></p>
<p>There was no clinically relevant pharmacokinetic interaction of
ranitidine or antacids containing aluminum and magnesium hydroxide
on telithromycin.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.6.4.7" id="section-11.2.6.4.7"></a>
<p class="First"><span class=
"Italics Underline">Paroxetine</span></p>
<p>There was no pharmacokinetic effect on paroxetine when KETEK was
co-administered.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.6.4.8" id="section-11.2.6.4.8"></a>
<p class="First"><span class=
"Italics Underline">Cisapride</span></p>
<p>Steady state peak plasma concentrations of cisapride (an agent
with the potential to increase QT interval) were increased by 95%
when co-administered with repeated doses of telithromycin,
resulting in significant increases in QTc. <span class=
"Italics">[see <a href="#S4.4">Contraindications
(4.4)</a>]</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.2.6.4.9" id="section-11.2.6.4.9"></a>
<p class="First"><span class="Italics Underline">OATP1B1 and
OATP1B3</span></p>
<p>In vitro studies using a model compound have shown that
telithromycin may act as an inhibitor for the hepatic uptake
transporters OATP1B1 and OATP1B3. Although the clinical relevance
of this finding is unknown, it is possible that concomitant
administration of KETEK with drugs that are substrates of OATP
family members could result in increased plasma concentrations of
the co-administered drug.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectioncode="49489-8"><a name="S12.4" id=
"S12.4"></a> <a name="section-11.3" id="section-11.3"></a>
<h2>12.4 Microbiology</h2>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.3.1" id="section-11.3.1"></a>
<p class="First"><span class="Bold">Mechanism of Action</span></p>
<p>Telithromycin belongs to the ketolide class of antibacterials
and is structurally related to the macrolides. Telithromycin blocks
protein synthesis by binding to domains II and V of 23S rRNA of the
50S ribosomal subunit. Telithromycin may also inhibit the assembly
of nascent ribosomal units.</p>
<p>Telithromycin concentrates in phagocytes where it exhibits
activity against intracellular respiratory pathogens. <span class=
"Italics">In vitro</span>, telithromycin has been shown to
demonstrate concentration-dependent bactericidal activity against
isolates of <span class="Italics">Streptococcus pneumoniae</span>
(including multi-drug resistant isolates [MDRSP<a class="Sup" href=
"#footnote-7" name="footnote-reference-7" id=
"footnote-reference-7">2</a>]).</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a href="#footnote-reference-7" name="footnote-7" id=
"footnote-7">2</a></dt>
<dd>MDRSP=Multi-drug resistant <span class="Italics">Streptococcus
pneumoniae</span> includes isolates known as PRSP
(penicillin-resistant <span class="Italics">Streptococcus
pneumoniae</span>), and are isolates resistant to two or more of
the following antimicrobials: penicillin, 2 <span class=
"Sup">nd</span> generation cephalosporins (e.g., cefuroxime),
macrolides, tetracyclines, and trimethoprim/sulfamethoxazole.</dd>
</dl>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.3.2" id="section-11.3.2"></a>
<p class="First"><span class="Bold">Mechanism of
Resistance</span></p>
<p>Production of Erm dimethyltransferases may cause telithromycin
resistance in some Gram-positive bacteria.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.3.3" id="section-11.3.3"></a>
<p class="First"><span class="Bold">List of
Microorganisms</span></p>
<p>Telithromycin has been shown to be active against most strains
of the following microorganisms, both <span class="Italics">in
vitro</span> and in clinical settings <span class="Italics">[see
<a href="#S1">Indications and Usage (1)</a>].</span></p>
<dl>
<dd><span class="Underline">Gram-positive bacteria</span><br>
<span class="Italics">Streptococcus pneumoniae</span> (including
MDRSP)</dd>
</dl>
<dl>
<dd><span class="Underline">Gram-negative bacteria</span><br>
<span class="Italics">Haemophilus influenzae<br>
Moraxella catarrhalis</span></dd>
</dl>
<dl>
<dd><span class="Underline">Other microorganisms</span><br>
<span class="Italics">Chlamydophila pneumoniae<br>
Mycoplasma pneumoniae</span></dd>
</dl>
<p>The following <span class="Italics">in vitro</span> data are
available, but their clinical significance is unknown.</p>
<p>At least 90% of the following microorganisms exhibit
<span class="Italics">in vitro</span> minimum inhibitory
concentrations (MICs) less than or equal to the susceptible
breakpoint for telithromycin. However, the safety and efficacy of
KETEK in treating clinical infections due to these microorganisms
have not been established in adequate and well-controlled clinical
trials.</p>
<dl>
<dd><span class="Underline">Gram-positive bacteria</span><br>
<span class="Italics">Staphylococcus aureus</span> (methicillin and
erythromycin susceptible isolates only)<br>
<span class="Italics">Streptococcus pyogenes</span> (erythromycin
susceptible isolates only)<br>
Beta-hemolytic streptococci (Lancefield groups C and G)</dd>
</dl>
<dl>
<dd><span class="Underline">Other microorganisms</span><br>
<span class="Italics">Legionella pneumophila</span></dd>
</dl>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.3.4" id="section-11.3.4"></a>
<p class="First"><span class="Bold">Susceptibility Test
Methods</span></p>
<p>When available, the clinical microbiology laboratory should
provide cumulative results of <span class="Italics">in vitro</span>
susceptibility test results for antimicrobial drugs used in local
hospitals and practice areas to the physician as periodic reports
that describe the susceptibility profile of nosocomial and
community-acquired pathogens. These reports should aid the
physician in selecting the most effective antimicrobial.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.3.4.1" id="section-11.3.4.1"></a>
<p class="First"><span class="Underline">Dilution
techniques</span></p>
<p>Quantitative methods are used to determine antimicrobial minimum
inhibitory concentrations (MICs). These MICs provide estimates of
the susceptibility of bacteria to antibacterial compounds. The MICs
should be determined using a standardized procedure. Standardized
procedures are based on dilution methods (broth or agar
dilution)<span class="Sup">1,3</span> or equivalent with
standardized inoculum and concentrations of telithromycin powder.
The MIC values should be interpreted according to criteria provided
in Table 6.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.3.4.2" id="section-11.3.4.2"></a>
<p class="First"><span class="Underline">Diffusion
techniques</span></p>
<p>Quantitative methods that require measurement of zone diameters
also provide reproducible estimates of the susceptibility of
bacteria to antibacterials. One such standardized
procedure<span class="Sup">2,3</span> requires the use of
standardized inoculum concentrations. This procedure uses paper
disks impregnated with 15 µg telithromycin to test the
susceptibility of microorganisms to telithromycin. Disc diffusion
zone sizes should be interpreted according to criteria in Table
6.</p>
<a name="table6" id="table6"></a>
<div class="scrollingtable">
<table width="90%">
<caption><span>Table 6 Susceptibility Test Result Interpretive
Criteria for Telithromycin</span></caption>
<colgroup>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%"></colgroup>
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center" rowspan="2">Pathogen</th>
<th class="Botrule Rrule" align="center" colspan="3">Minimum
Inhibitory Concentrations<br>
(µg/mL)</th>
<th class="Botrule Rrule" align="center" colspan="3">Disk Diffusion
Zone Diameter<br>
(mm)</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">S</th>
<th class="Rrule" align="center">I</th>
<th class="Rrule" align="center">R</th>
<th class="Rrule" align="center">S</th>
<th class="Rrule" align="center">I</th>
<th class="Rrule" align="center">R</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class=
"Italics">Streptococcus pneumoniae</span></td>
<td class="Rrule" align="center">≤1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">≥4</td>
<td class="Rrule" align="center">≥19</td>
<td class="Rrule" align="center">16–18</td>
<td class="Rrule" align="center">≤15</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class=
"Italics">Haemophilus influenzae</span></td>
<td class="Rrule" align="center">≤4</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">≥16</td>
<td class="Rrule" align="center">≥15</td>
<td class="Rrule" align="center">12–14</td>
<td class="Rrule" align="center">≤11</td>
</tr>
</tbody>
</table>
</div>
<p>A report of "Susceptible" indicates that the antimicrobial is
likely to inhibit growth of the pathogen if the antibacterial
compound in the blood reaches the concentrations usually
achievable. A report of "Intermediate" indicates that the result
should be considered equivocal, and, if the microorganism is not
fully susceptible to alternative, clinically feasible drugs, the
test should be repeated. This category implies possible clinical
applicability in body sites where the drug is physiologically
concentrated or in situations where high dosage of drug can be
used. This category also provides a buffer zone that prevents small
uncontrolled technical factors from causing major discrepancies in
interpretation. A report of "Resistant" indicates that the
antimicrobial is not likely to inhibit growth of the pathogen if
the antimicrobial compound in the blood reaches the concentrations
usually achievable; other therapy should be selected.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-11.3.4.3" id="section-11.3.4.3"></a>
<p class="First"><span class="Underline">Quality control</span></p>
<p>Standardized susceptibility test procedures require the use of
quality control microorganisms to determine the performance of the
test procedures<span class="Sup">1,2,3</span>. Standard
telithromycin powder should provide the MIC ranges for the quality
control organisms in Table 7. For the disk diffusion technique, the
15-μg telithromycin disk should provide the zone diameter ranges
for the quality control organisms in Table 7.</p>
<a name="table7" id="table7"></a>
<div class="scrollingtable">
<table width="75%">
<caption><span>Table 7 Acceptable Quality Control Ranges for
Telithromycin</span></caption>
<colgroup>
<col align="left" valign="middle" width="34%">
<col align="center" valign="middle" width="33%">
<col align="center" valign="middle" width="33%"></colgroup>
<thead>
<tr class="First Last">
<th class="Lrule Rrule" align="center">Quality Control
Organism</th>
<th class="Rrule" align="center">Minimum Inhibitory Concentrations
(µg/mL)</th>
<th class="Rrule" align="center">Disk Diffusion<br>
(zone diameter in mm)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last">
<td align="left" colspan="3">ATCC = American Type Culture
Collection</td>
</tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class=
"Italics">Haemophilus influenzae</span><br>
ATCC 49247</td>
<td class="Rrule" align="center">1.0–4.0</td>
<td class="Rrule" align="center">17–23</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class=
"Italics">Streptococcus pneumoniae</span><br>
ATCC 49619</td>
<td class="Rrule" align="center">0.004–0.03</td>
<td class="Rrule" align="center">27–33</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">13 NONCLINICAL TOXICOLOGY</a>
<div class="Section toggle-content closed" data-sectioncode=
"43680-8"><a name="S13" id="S13"></a> <a name="section-12" id=
"section-12"></a>
<div class="Section" data-sectioncode="34083-6"><a name="S13.1" id=
"S13.1"></a> <a name="section-12.1" id="section-12.1"></a>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals to determine the
carcinogenic potential of KETEK have not been conducted.</p>
<p>Telithromycin showed no evidence of genotoxicity in four tests:
gene mutation in bacterial cells, gene mutation in mammalian cells,
chromosome aberration in human lymphocytes, and the micronucleus
test in the mouse.</p>
<p>No evidence of impaired fertility in the rat was observed at
doses estimated to be 0.6 times the human daily dose on a body
surface area basis (50 mg/kg/day). At doses of 2–4 times the human
daily dose (150 and 300 mg/kg/day, at which signs of parental
toxicity were observed), moderate reductions in fertility indices
were noted in male and female animals treated with
telithromycin.</p>
</div>
<div class="Section" data-sectioncode="34091-9"><a name="S13.2" id=
"S13.2"></a> <a name="section-12.2" id="section-12.2"></a>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">Repeated dose toxicity studies of 1, 3, and 6
months' duration with telithromycin conducted in rat, dog and
monkey showed that the liver was the principal target for toxicity
with elevations of liver enzymes and histological evidence of
damage. There was evidence of reversibility after cessation of
treatment. Plasma exposures based on free fraction of drug at the
no observed adverse effect levels ranged from 1 to 10 times the
expected clinical exposure.</p>
<p>Phospholipidosis (intracellular phospholipid accumulation)
affecting a number of organs and tissues (e.g., liver, kidney,
lung, thymus, spleen, gall bladder, mesenteric lymph nodes,
GI-tract) has been observed with the administration of
telithromycin in rats at repeated doses of 150 mg/kg/day ( 2× the
human dose on a body surface area basis) or more for 1 month, and
50 mg/kg/day (0.6× the human dose) or more for 3–6 months.
Similarly, phospholipidosis has been observed in dogs with
telithromycin at repeated doses of 150 mg/kg/day (6× the human dose
on a body surface area basis) or more for 1 month and 50 mg/kg/day
(2× the human dose) or more for 3 months. The significance of these
findings for humans is unknown.</p>
<p>Pharmacology/toxicology studies showed an effect both in
prolonging QTc interval in dogs <span class="Italics">in
vivo</span> and <span class="Italics">in vitro</span> action
potential duration (APD) in rabbit Purkinje fibers. These effects
were observed at concentrations of free drug at least 8.8 (in dogs)
times those circulating in clinical use. <span class="Italics">In
vitro</span> electrophysiological studies (hERG assays) suggested
an inhibition of the rapid activating component of the delayed
rectifier potassium current (I<span class="Sub">Kr</span>) as an
underlying mechanism.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">14 CLINICAL STUDIES</a>
<div class="Section toggle-content closed" data-sectioncode=
"34092-7"><a name="S14" id="S14"></a> <a name="section-13" id=
"section-13"></a>
<p class="First">KETEK was studied in four randomized,
double-blind, controlled studies and four open-label studies for
the treatment of community-acquired pneumonia (CAP). Patients with
mild to moderate CAP who were considered appropriate for oral
outpatient treatment were enrolled in these trials. Patients with
severe pneumonia were excluded based on any one of the following:
ICU admission, need for parenteral antibacterials, respiratory rate
greater than 30 per minute, hypotension, altered mental status,
less than 90% oxygen saturation by pulse oximetry, or white blood
cell count less than 4000 per mm<span class="Sup">3</span>. There
were 2016 clinically evaluable patients in the KETEK group.</p>
<a name="table8" id="table8"></a>
<div class="scrollingtable">
<table width="90%">
<caption><span>Table 8. CAP: Clinical Cure Rate at Post-Therapy
Follow-Up (17–24 days)</span></caption>
<colgroup>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%"></colgroup>
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">Patients (n)</th>
<th class="Rrule" align="center" colspan="2">Clinical Cure
Rate</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">Controlled Studies</th>
<th class="Rrule" align="center">KETEK</th>
<th class="Rrule" align="center">Comparator</th>
<th class="Rrule" align="center">KETEK</th>
<th class="Rrule" align="center">Comparator</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="5">
<dl class="Footnote">
<dt><a href="#footnote-reference-8" name="footnote-8" id=
"footnote-8">*</a></dt>
<dd>This study was stopped prematurely after trovafloxacin was
restricted for use in hospitalized patients with severe
infection.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">KETEK vs. clarithromycin 500
mg twice a day for 10 days</td>
<td class="Rrule" align="center">162</td>
<td class="Rrule" align="center">156</td>
<td class="Rrule" align="center">88.3%</td>
<td class="Rrule" align="center">88.5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">KETEK vs.
trovafloxacin<a class="Sup" href="#footnote-8" name=
"footnote-reference-8" id="footnote-reference-8">*</a> 200 mg daily
for 7 to 10 days</td>
<td class="Rrule" align="center">80</td>
<td class="Rrule" align="center">86</td>
<td class="Rrule" align="center">90.0%</td>
<td class="Rrule" align="center">94.2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">KETEK vs. amoxicillin 1000 mg
three times a day for 10 days</td>
<td class="Rrule" align="center">149</td>
<td class="Rrule" align="center">152</td>
<td class="Rrule" align="center">94.6%</td>
<td class="Rrule" align="center">90.1%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">KETEK for 7 days vs.
clarithromycin 500 mg twice a day for 10 days</td>
<td class="Rrule" align="center">161</td>
<td class="Rrule" align="center">146</td>
<td class="Rrule" align="center">88.8%</td>
<td class="Rrule" align="center">91.8%</td>
</tr>
</tbody>
</table>
</div>
<p>Clinical cure rates by pathogen from the four CAP controlled
clinical trials in microbiologically evaluable patients given KETEK
for 7–10 days or a comparator are displayed in Table 9.</p>
<a name="table9" id="table9"></a>
<div class="scrollingtable">
<table width="80%">
<caption><span>Table 9. CAP: Clinical Cure Rate by Pathogen at
Post-Therapy Follow-Up (17–24 days)</span></caption>
<colgroup>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%"></colgroup>
<thead>
<tr class="First Last">
<th class="Lrule Rrule" align="center">Pathogen</th>
<th class="Rrule" align="center">KETEK</th>
<th class="Rrule" align="center">Comparator</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class=
"Italics">Streptococcus pneumoniae</span></td>
<td class="Rrule" align="center">73/78 (93.6%)</td>
<td class="Rrule" align="center">63/70 (90%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class=
"Italics">Haemophilus influenzae</span></td>
<td class="Rrule" align="center">39/47 (83%)</td>
<td class="Rrule" align="center">42/44 (95.5%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class=
"Italics">Moraxella catarrhalis</span></td>
<td class="Rrule" align="center">12/14 (85.7%)</td>
<td class="Rrule" align="center">7/9 (77.8%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class=
"Italics">Chlamydophila pneumoniae</span></td>
<td class="Rrule" align="center">23/25 (92%)</td>
<td class="Rrule" align="center">18/19 (94.7%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class=
"Italics">Mycoplasma pneumoniae</span></td>
<td class="Rrule" align="center">22/23 (95.7%)</td>
<td class="Rrule" align="center">20/22 (90.9%)</td>
</tr>
</tbody>
</table>
</div>
<p>Clinical cure rates for patients with CAP due to <span class=
"Italics">Streptococcus pneumoniae</span> were determined from
patients in controlled and uncontrolled trials. Of 333 evaluable
patients with CAP due to <span class="Italics">Streptococcus
pneumoniae</span>, 312 (93.7%) achieved clinical success. Blood
cultures were obtained in all patients participating in the
clinical trials of mild to moderate community-acquired pneumonia.
In a limited number of outpatients with incidental pneumococcal
bacteremia treated with KETEK, a clinical cure rate of 88% (67/76)
was observed. KETEK is not indicated for the treatment of severe
community-acquired pneumonia or suspected pneumococcal
bacteremia.</p>
<p>Clinical cure rates for patients with CAP due to multi-drug
resistant <span class="Italics">Streptococcus pneumoniae</span>
(MDRSP<a class="Sup" href="#footnote-9" name="footnote-reference-9"
id="footnote-reference-9">3</a>) were determined from patients in
controlled and uncontrolled trials. Of 36 evaluable patients with
CAP due to MDRSP, 33 (91.7%) achieved clinical success.</p>
<a name="table10" id="table10"></a>
<div class="scrollingtable">
<table width="65%">
<caption><span>Table 10. Clinical Cure Rate for 36 Evaluable
KETEK-Treated Patients with MDRSP in Studies of Community-Acquired
Pneumonia</span></caption>
<colgroup>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="30%"></colgroup>
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center">Screening
Susceptibility</th>
<th class="Rrule" align="center" colspan="2">Clinical Success in
Evaluable MDRSP Patients</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">n/N<a class="Sup" href=
"#footnote-10" name="footnote-reference-10" id=
"footnote-reference-10">*</a></th>
<th class="Rrule" align="center">%</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<dl class="Footnote">
<dt><a href="#footnote-reference-10" name="footnote-10" id=
"footnote-10">*</a></dt>
<dd>n = the number of patients successfully treated; N = the number
with resistance to the listed drug of the 36 evaluable patients
with CAP due to MDRSP.</dd>
<dt><a href="#footnote-reference-11" name="footnote-11" id=
"footnote-11">†</a></dt>
<dd>Includes isolates tested for resistance to either tetracycline
or doxycycline.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Penicillin-resistant</td>
<td class="Rrule" align="center">20/23</td>
<td class="Rrule" align="center">86.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">2<span class="Sup">nd</span>
generation<br>
cephalosporin-resistant</td>
<td class="Rrule" align="center">20/22</td>
<td class="Rrule" align="center">90.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Macrolide-resistant</td>
<td class="Rrule" align="center">25/28</td>
<td class="Rrule" align="center">89.3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Trimethoprim/<br>
sulfamethoxazole-resistant</td>
<td class="Rrule" align="center">24/27</td>
<td class="Rrule" align="center">88.9</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">
Tetracycline-resistant<a class="Sup" href="#footnote-11" name=
"footnote-reference-11" id="footnote-reference-11">†</a></td>
<td class="Rrule" align="center">11/13</td>
<td class="Rrule" align="center">84.6</td>
</tr>
</tbody>
</table>
</div>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a href="#footnote-reference-9" name="footnote-9" id=
"footnote-9">3</a></dt>
<dd>MDRSP: Multi-drug resistant <span class="Italics">Streptococcus
pneumoniae</span> includes isolates known as PRSP
(penicillin-resistant <span class="Italics">Streptococcus
pneumoniae)</span>, and are isolates resistant to two or more of
the following antibacterials: penicillin, 2 <span class=
"Sup">nd</span> generation cephalosporins, e.g., cefuroxime,
macrolides, tetracyclines and trimethoprim/sulfamethoxazole.</dd>
</dl>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">15 References</a>
<div class="Section toggle-content closed" data-sectioncode=
"34093-5"><a name="S15" id="S15"></a> <a name="section-14" id=
"section-14"></a>
<dl>
<dt>1.</dt>
<dd>Clinical and Laboratory Standards Institute (CLSI).
<span class="Italics">Methods for Dilution Antimicrobial
Susceptibility Tests for Bacteria that Grow Aerobically; Approved
Standard - Ninth Edition</span>. CLSI document M07-A9, Clinical and
Laboratory Standards Institute, 950 West Valley Road, Suite 2500,
Wayne, Pennsylvania 19087, USA, 2012.</dd>
<dt>2.</dt>
<dd>Clinical and Laboratory Standards Institute (CLSI).
<span class="Italics">Performance Standards for Antimicrobial Disk
Diffusion Susceptibility Tests; Approved Standard – Eleventh
Edition.</span> CLSI document M02-A11, Clinical and Laboratory
Standards Institute, 950 West Valley Road, Suite 2500, Wayne,
Pennsylvania 19087, USA, 2012.</dd>
<dt>3.</dt>
<dd>Clinical and Laboratory Standards Institute (CLSI).
<span class="Italics">Performance Standards for Antimicrobial
Susceptibility Testing; Twenty-third Informational
Supplement</span>, CLSI document M100-S24, Clinical and Laboratory
Standards Institute, 950 West Valley Road, Suite 2500, Wayne,
Pennsylvania 19087, USA, 2014.</dd>
</dl>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">16 HOW SUPPLIED/STORAGE AND HANDLING</a>
<div class="Section toggle-content closed" data-sectioncode=
"34069-5"><a name="S16" id="S16"></a> <a name="section-15" id=
"section-15"></a>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-15.1" id="section-15.1"></a>
<p class="First"><span class="Underline">How Supplied</span></p>
<p>KETEK<span class="Sup">®</span> 400 mg tablets are supplied as
light-orange, oval, film-coated tablets, imprinted "H3647" on one
side and "400" on the other side.</p>
<div class="scrollingtable">
<table class="Noautorules" width="50%">
<colgroup>
<col align="left" valign="top" width="50%">
<col align="right" valign="top" width="50%"></colgroup>
<tbody class="Headless">
<tr>
<td align="left">Bottles of 60</td>
<td align="right">(NDC 0088-2225-41)</td>
</tr>
</tbody>
</table>
</div>
<p>KETEK<span class="Sup">®</span> 300 mg tablets are supplied as
light-orange, oval, film-coated tablets, imprinted "38AV" on one
side and blank on the other side.</p>
<div class="scrollingtable">
<table class="Noautorules" width="50%">
<colgroup>
<col align="left" valign="top" width="50%">
<col align="right" valign="top" width="50%"></colgroup>
<tbody class="Headless">
<tr>
<td align="left">Bottles of 20</td>
<td align="right">(NDC 0088-2223-20)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectioncode="44425-7"><a name=
"section-15.2" id="section-15.2"></a>
<p class="First"><span class="Underline">Storage</span></p>
<p>Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F)
[see USP Controlled Room Temperature].</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">17 PATIENT COUNSELING INFORMATION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34076-0"><a name="S17" id="S17"></a> <a name="section-16" id=
"section-16"></a>
<p class="First">Advise the patient to read the FDA-approved
patient labeling (MEDICATION GUIDE).</p>
<p>Communicate the following information and instructions to the
patient:</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.1" id="section-16.1"></a>
<ul class="Disc">
<li><span class="Bold">Drug Resistance</span></li>
</ul>
<p class="First">Antibacterial drugs including KETEK should only be
used to treat bacterial infections. They do not treat viral
infections (e.g., the common cold). When KETEK is prescribed to
treat a bacterial infection, inform patients that although it is
common to feel better early in the course of therapy, the
medication should be taken exactly as directed. Skipping doses or
not completing the full course of therapy may (1) decrease the
effectiveness of the immediate treatment and (2) increase the
likelihood that bacteria will develop resistance and will not be
treatable by KETEK or other antibacterial drugs in the future.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.2" id="section-16.2"></a>
<ul class="Disc">
<li><span class="Bold">Myasthenia Gravis</span></li>
</ul>
<p class="First">Advise patients not to take KETEK if they have
myasthenia gravis <span class="Italics">[see <a href=
"#S4.1">Contraindications (4.1)</a>]</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.3" id="section-16.3"></a>
<ul class="Disc">
<li><span class="Bold">Liver Injury</span></li>
</ul>
<p class="First">Advise patients of the possibility of severe liver
injury, associated with KETEK. Instruct them to discontinue KETEK
and seek medical attention immediately if they develop nausea,
fatigue, anorexia, jaundice, dark urine, light-colored stools,
pruritus, or tender abdomen. These problems may occur after any
dose during treatment or after treatment had stopped. Advise
patients not to take KETEK if they have a previous history of
hepatitis/jaundice associated with the use of KETEK or macrolide
antibacterials. <span class="Italics">[see <a href=
"#S4.2">Contraindications (4.2)</a>; <a href="#S5.1">Warnings and
Precautions (5.1)</a>]</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.4" id="section-16.4"></a>
<ul class="Disc">
<li><span class="Bold">Changes in Electrocardiogram</span></li>
</ul>
<p class="First">KETEK may produce changes in the electrocardiogram
(QTc interval prolongation). Advise patient to report any fainting
or palpitations occurring during drug treatment. <span class=
"Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>;
<a href="#S6.2">Adverse Reactions (6.2)</a>]</span></p>
<p>Advise patients to avoid KETEK if they are receiving Class 1A
(e.g., quinidine, procainamide) or Class III (e.g., dofetilide)
antiarrhythmic agents.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.5" id="section-16.5"></a>
<ul class="Disc">
<li><span class="Bold">Problems with Vision and Loss of
Consciousness</span></li>
</ul>
<p class="First">KETEK may cause blurred vision, difficulty
focusing, and objects looking doubled. These problems may occur
after any dose during treatment, last for several hours, and come
back with the next dose. <span class="Italics">[</span><span class=
"Italics">See <a href="#S5.3">Warnings and Precautions (5.3)</a>;
<a href="#S6.1">Adverse Reactions (6.1)</a>]</span></p>
<p>KETEK may also cause transient loss of consciousness.
<span class="Italics">[</span><span class="Italics">See <a href=
"#S5.3">Warnings and Precautions (5.3)</a>]</span></p>
<p>Advise patients to avoid quick changes in viewing between
objects in the distance and objects nearby to help decrease the
effects of these visual difficulties.</p>
<p>Advise patients to minimize activities such as driving a motor
vehicle, operating heavy machinery or engaging in other hazardous
activities during treatment with KETEK, because of potential visual
difficulties, loss of consciousness, confusion or
hallucinations.</p>
<p>Advise patients that if visual difficulties, loss of
consciousness / fainting, confusion or hallucination occur, to seek
advice from their physician before taking another dose and to
refrain from hazardous activities.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.6" id="section-16.6"></a>
<ul class="Disc">
<li><span class="Bold">Drug/Food Interactions</span></li>
</ul>
<p class="First">Advise patients that KETEK tablets can be taken
with or without food.</p>
<p>Colchicine should be avoided in patients receiving KETEK. Advise
patients with normal kidney and liver function that the dose of
colchicine should be reduced while they are taking KETEK.
<span class="Italics">[see <a href="#S5.4">Warnings and Precautions
(5.4)</a>; <a href="#S7">Drug Interactions (7)</a>]</span></p>
<p>Simvastatin, lovastatin, or atorvastatin should be avoided in
patients receiving KETEK. Advise patients that KETEK therapy with
simvastatin, lovastatin, or atorvastatin should be stopped during
the course of treatment with KETEK due to increased risk of
rhabdomyolysis. <span class="Italics">[see <a href="#S5.4">Warnings
and Precautions (5.4)</a>; <a href="#S7">Drug Interactions
(7)</a>]</span></p>
<p>Taking KETEK with calcium channel blockers may cause severe
hypotension, bradycardia and loss of consciousness. Advise patients
that if these symptoms occur to contact their physician as soon as
possible. <span class="Italics">[see <a href="#S5.4">Warnings and
Precautions (5.4)</a>; <a href="#S7">Drug Interactions
(7)</a>]</span></p>
<p>Advise patients to inform their physician of any other
medications taken concurrently with KETEK, including
over-the-counter medications and dietary supplements.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.7" id="section-16.7"></a>
<ul class="Disc">
<li><span class="Bold">Diarrhea</span></li>
</ul>
<p class="First">Diarrhea is a common problem caused by
antibacterials including KETEK which usually ends when the
antibacterial is discontinued. Sometimes after starting treatment
with antibacterials, patients can develop watery and bloody stools
(with or without stomach cramps and fever) even as late as two or
more months after having taken the last dose of the antibacterial.
If this occurs, patients should contact their physician as soon as
possible. <span class="Italics">[see <a href="#S5.5">Warnings and
Precautions (5.5)</a>]</span></p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">SPL UNCLASSIFIED SECTION</a>
<div class="Section toggle-content closed" data-sectioncode=
"42229-5"><a name="section-17" id="section-17"></a>
<p class="First">Manufactured for:<br>
sanofi-aventis U.S. LLC<br>
Bridgewater, NJ 08807<br>
A SANOFI COMPANY</p>
<p>© 2015 sanofi-aventis U.S. LLC</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">MEDICATION GUIDE</a>
<div class="Section toggle-content closed" data-sectioncode=
"42231-1"><a name="medguide" id="medguide"></a> <a name=
"section-18" id="section-18"></a>
<p class="First"><span class="Bold">KETEK<span class="Sup">®</span>
(<span class="Italics">KEE tek</span>)<br>
(telithromycin)<br>
Tablets</span></p>
<p>Read this Medication Guide before you start taking KETEK and
each time you get a new prescription. There may be new information.
This Medication Guide does not take the place of talking with your
doctor about your medical condition or your treatment.</p>
<p><a name="important" id="important"></a><span class="Bold">WHAT
IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT
KETEK?</span></p>
<p><span class="Bold">KETEK can cause serious side effects,
including:</span></p>
<ul class="Disc">
<li><span class="Bold">Worsening of myasthenia gravis symptoms in
people who already have myasthenia gravis (a disease which causes
muscle weakness). Worsening of myasthenia gravis symptoms,
including life-threatening breathing problems, have happened in
people with myasthenia gravis after taking KETEK. Some
life-threatening breathing problems have caused death. Do not take
KETEK if you have myasthenia gravis.</span></li>
</ul>
<p><span class="Bold">WHAT IS KETEK?</span></p>
<p>KETEK is a prescription medication used to treat mild to
moderate community-acquired pneumonia in adults 18 years of age and
older.</p>
<ul class="Disc">
<li>KETEK is only used to treat certain types of bacteria and is
not meant for use to treat all types of bacterial infections.<br>
It is not known if KETEK is safe and effective in children.</li>
</ul>
<p><span class="Bold">Who should not take KETEK?</span></p>
<p>Do not take KETEK if you:</p>
<ul class="Disc">
<li>have myasthenia gravis.</li>
<li>have had liver problems or yellowing of your eyes and/or skin
(jaundice) while taking KETEK or macrolide antibacterials.</li>
<li>are allergic to KETEK, or macrolide antibacterials.</li>
<li>take cisapride or pimozide.</li>
<li>take colchicine and have kidney or liver problems.</li>
</ul>
<p><span class="Bold">What should I tell my doctor before taking
KETEK?</span></p>
<p><span class="Bold">Before you take KETEK, tell your doctor if
you:</span></p>
<ul class="Disc">
<li>have or have had liver or kidney problems</li>
<li>have a heart problem called "QTc prolongation" or have a family
history of QTc prolongation</li>
<li>have other heart problems</li>
<li>are pregnant or plan to become pregnant. It is not known if
KETEK will harm your unborn baby. Talk to your doctor if you are
pregnant or plan to become pregnant.</li>
<li>are breast-feeding or plan to breast-feed. It is not known if
KETEK passes into your breast milk. Talk to your doctor about the
best way to feed your baby if you take KETEK.</li>
</ul>
<p><span class="Bold">Tell your doctor about all of the medicines
you take,</span> including prescription and over-the-counter
medicines, vitamins, and herbal supplements.</p>
<p>Taking KETEK with other medicines can cause serious side
effects. Ask your doctor for a list of these medicines if you are
not sure.</p>
<p><span class="Bold">Know the medicines you take.</span> Keep a
list of them to show your doctor and pharmacist when you get a new
medicine.</p>
<p><span class="Bold">How should I take KETEK?</span></p>
<ul class="Disc">
<li>Take KETEK exactly as your doctor tells you to take it.</li>
<li>If you have kidney problems, your doctor may prescribe a lower
dose of KETEK for you.</li>
<li>Take KETEK with or without food.</li>
<li>If you take too much KETEK, call your doctor, or go to the
nearest hospital emergency room right away.</li>
</ul>
<p><a name="avoid" id="avoid"></a><span class="Bold">What should I
avoid while taking KETEK?</span></p>
<ul class="Disc">
<li><span class="Bold">Do not</span> drive, operate heavy
machinery, or do other dangerous activities until you know how
KETEK affects you.</li>
</ul>
<p><span class="Bold">What are the possible side effects of
KETEK?</span></p>
<p>KETEK may cause serious side effects, including:</p>
<ul class="Disc">
<li>See <span class="Bold">"<a href="#important">What is the most
important information I should know about KETEK?</a>"</span></li>
<li><span class="Bold">severe liver problems and severe liver
damage (hepatotoxicity) that can lead to liver transplant or
death</span>. Severe liver problems can happen while you take
KETEK, even after a few doses or right after you stop taking it.
Symptoms of liver problems may include:
<ul class="Circle">
<li>loss of appetite</li>
<li>increased tiredness</li>
<li>nausea</li>
<li>yellowing of your skin or white of your eyes</li>
<li>dark colored urine (tea colored)</li>
<li>light colored stools</li>
<li>right upper belly (abdomen) pain</li>
</ul>
</li>
<li><span class="Bold">a heart problem called QTc prolongation that
can lead to death.</span> Symptoms of QTc prolongation include
fainting and fast heartbeat (heart palpitations). Call your doctor
right away if you have these symptoms.</li>
<li><span class="Bold">vision problems.</span> KETEK may cause you
to have blurred vision, trouble focusing your eyes, and double
vision. You may especially notice vision problems if you look
quickly between objects close to you and objects far away from
you.</li>
<li><span class="Bold">fainting.</span> KETEK may cause you to
faint, especially if you also have nausea, vomiting, and
lightheadedness (vagal syndrome). See <span class="Bold">"<a href=
"#avoid">What should I avoid while taking KETEK?</a>"</span></li>
<li><span class="Bold">drug interaction with colchicine in people
with normal kidney and liver function that may lead to
death.</span></li>
<li><span class="Bold">severe muscle damage
(rhabdomyolysis).</span> KETEK may cause rhabdomyolysis when you
also take certain medicines used to treat high levels of
cholesterol in your blood. These medicines include:
<ul class="Circle">
<li>simvastatin</li>
<li>lovastatin</li>
<li>atorvastatin</li>
</ul>
</li>
<li><span class="Bold">low blood pressure, slow heart rate, and
fainting.</span> KETEK may cause you to have low blood pressure, a
slow heart rate, and fainting when you also take certain medicines
called calcium channel blockers. Calcium channel blockers include:
<ul class="Circle">
<li>verapamil</li>
<li>amlodipine</li>
<li>diltiazem</li>
<li>or other medicines containing these products</li>
</ul>
</li>
<li><span class="Bold">an intestinal infection (Clostridium
<span class="Italics">difficile</span>-associated diarrhea)</span>.
<span class="Italics">Clostridium difficile</span>-associated
diarrhea can happen up to 2 months after you have stopped taking
KETEK. Symptoms of <span class="Italics">Clostridium
difficile</span>-associated diarrhea may include:
<ul class="Circle">
<li>watery diarrhea</li>
<li>diarrhea that does not go away</li>
<li>bloody stools</li>
<li>stomach cramps</li>
<li>fever</li>
</ul>
</li>
</ul>
<p><span class="Bold">Stop taking KETEK and call your doctor right
away if you have any of these symptoms listed above. Do not</span>
take another dose of KETEK unless your doctor tells you to.</p>
<p>The most common side effects of KETEK include:</p>
<ul>
<li>diarrhea</li>
<li>nausea</li>
<li>dizziness</li>
<li>vomiting</li>
</ul>
<p>Tell your doctor if you have any side effect that bothers you or
that does not go away.</p>
<p>These are not all of the possible side effects of KETEK. For
more information ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may
report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store KETEK?</span></p>
<ul class="Disc">
<li>Store KETEK tablets at room temperature, between 59°F to 86°F
(15°C to 30°C).</li>
<li><span class="Bold">Keep KETEK and all medicines out of the
reach of children.</span></li>
</ul>
<p><span class="Bold">General information about the safe and
effective use of KETEK</span></p>
<p>Medicines are sometimes prescribed for purposes other than those
listed in a Medication Guide. Do not use KETEK for a condition for
which it was not prescribed. Do not share KETEK with other people,
even if they have the same symptoms that you have. It may harm
them.</p>
<p>This Medication Guide summarizes the most important information
about KETEK. If you would like more information, talk with your
doctor. You can ask your pharmacist or doctor for information about
KETEK that is written for health professionals. For more
information, go to www.KETEK.com or call 1-800-446-6267.</p>
<p><span class="Bold">What are the ingredients in KETEK?</span></p>
<p><span class="Bold">Active Ingredient:</span> telithromycin</p>
<p><span class="Bold">Inactive Ingredients:</span> croscarmellose
sodium, hypromellose, magnesium stearate, microcrystalline
cellulose, polyethylene glycol, povidone, red ferric oxide, talc,
titanium dioxide, and yellow ferric oxide</p>
<p>This Medication Guide has been approved by the U.S. Food and
Drug Administration.</p>
<p>Manufactured for:<br>
sanofi-aventis U.S. LLC<br>
Bridgewater, NJ 08807<br>
A SANOFI COMPANY</p>
<p>Revised: December 2015</p>
<p>© 2015 sanofi-aventis U.S. LLC</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL - 400 mg Tablet Bottle
Label</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="section-19" id="section-19"></a>
<p class="First">NDC 0088-2225-41</p>
<p><span class="Bold">Ketek<span class="Sup">®</span></span><br>
TELITHROMYCIN<br>
<span class="Bold">400</span>mg</p>
<p><span class="Bold">Dispense with attached Medication
Guide</span></p>
<p><span class="Bold">60</span> Tablets</p>
<p><span class="Bold">SANOFI</span></p>
<div class="Figure"><img src=
"image.cfm?setid=4471223e-9023-457e-be2e-8e4e0c2d94d1&amp;name=ketek-02.jpg"
alt="Principal Display Panel - 400 mg Tablet Bottle Label"></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL - 300 mg Tablet Bottle
Label</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="section-20" id="section-20"></a>
<p class="First">NDC 0088-2223-20</p>
<p><span class="Bold">Ketek<span class="Sup">®</span></span><br>
TELITHROMYCIN<br>
<span class="Bold">300</span>mg</p>
<p><span class="Bold">Dispense with attached Medication
Guide</span></p>
<p><span class="Bold">20</span> Tablets</p>
<p><span class="Bold">SANOFI</span></p>
<div class="Figure"><img src=
"image.cfm?setid=4471223e-9023-457e-be2e-8e4e0c2d94d1&amp;name=ketek-03.jpg"
alt="Principal Display Panel - 300 mg Tablet Bottle Label"></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">INGREDIENTS AND APPEARANCE</a>
<div class="DataElementsTables toggle-content">
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>KETEK</strong><br>
<span class="contentTableReg">telithromycin tablet, film
coated</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0088-2225</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>telithromycin</strong> (UNII:
KI8H7H19WL) (telithromycin - UNII:KI8H7H19WL)</td>
<td class="formItem">telithromycin</td>
<td class="formItem">400 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong> (UNII:
M28OL1HH48)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromelloses</strong> (UNII:
3NXW29V3WO)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycols</strong> (UNII:
3WJQ0SDW1A)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidones</strong> (UNII:
FZ989GH94E)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong> (UNII:
1K09F3G675)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>talc</strong> (UNII: 7SEV7J4R1U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong> (UNII:
15FIX9V2JP)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide yellow</strong> (UNII:
EX438O2MRT)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">H3647;400</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0088-2225-41</td>
<td class="formItem">60 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021144</td>
<td class="formItem">06/01/2010</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>KETEK</strong><br>
<span class="contentTableReg">telithromycin tablet, film
coated</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0088-2223</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>telithromycin</strong> (UNII:
KI8H7H19WL) (telithromycin - UNII:KI8H7H19WL)</td>
<td class="formItem">telithromycin</td>
<td class="formItem">300 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong> (UNII:
M28OL1HH48)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromelloses</strong> (UNII:
3NXW29V3WO)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycols</strong> (UNII:
3WJQ0SDW1A)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidones</strong> (UNII:
FZ989GH94E)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong> (UNII:
1K09F3G675)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>talc</strong> (UNII: 7SEV7J4R1U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong> (UNII:
15FIX9V2JP)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide yellow</strong> (UNII:
EX438O2MRT)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">38AV</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0088-2223-20</td>
<td class="formItem">20 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021144</td>
<td class="formItem">06/01/2010</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Labeler -</span> sanofi-aventis U.S. LLC
(783243835)</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Establishment</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Name</th>
<th class="formTitle" scope="col">Address</th>
<th class="formTitle" scope="col">ID/FEI</th>
<th class="formTitle" scope="col">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">sanofi-aventis U.S. LLC</td>
<td class="formItem"></td>
<td class="formItem">783243835</td>
<td class="formItem">MANUFACTURE(0088-2225, 0088-2223)</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Establishment</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Name</th>
<th class="formTitle" scope="col">Address</th>
<th class="formTitle" scope="col">ID/FEI</th>
<th class="formTitle" scope="col">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">AAI Pharma Services Corp.</td>
<td class="formItem"></td>
<td class="formItem">832395235</td>
<td class="formItem">MANUFACTURE(0088-2225, 0088-2223) ,
ANALYSIS(0088-2225, 0088-2223) , LABEL(0088-2225, 0088-2223) ,
PACK(0088-2225, 0088-2223)</td>
</tr>
</tbody>
</table>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
</ul>
<div class="control-nav"><a class="open-all" href="#">View All
Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
</div>
</div>
</article>
<div class="articlefooternav">
<h2>Find additional resources</h2>
<strong>(also available in the <a href="#leftmenu">left
menu</a>)</strong>
<h3>Safety</h3>
<p><a href="#boxedwarning" target="_blank">Boxed Warnings</a>,
<a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a>, <a href=
"http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety
Recalls</a>, <a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22telithromycin%22+%29"
target="_blank">Presence in Breast Milk</a></p>
<h3>Related Resources</h3>
<p><a href=
"http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=telithromycin"
target="_blank">Medline Plus</a>, <a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=telithromycin"
target="_blank">Clinical Trials</a>, <a href="#pubmed-menu" id=
"pubmed-bottom">PubMed</a>, <a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=APRD00483&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></p>
<h3>More Info on this Drug</h3>
<p><a href="#modal-label-archives" class="modal-open">View Label
Archives</a>, <a href="#modal-rx-norm" class=
"modal-open">RxNorm</a>, <a href="#modal-label-rss" class=
"modal-open">Get Label RSS Feed</a></p>
</div>
</div>
<div class="divider"></div>
</div>
</div>
<!-- Label Archives Modal -->
<div class="mfp-hide modal" id="modal-label-archives">
<div class="modal-wrapper">
<header>
<h2>View Label Archives for this drug</h2>
</header>
<div class="top">
<h3 class="long-title">KETEK- telithromycin tablet, film
coated<br></h3>
<h4>Number of versions: 10</h4>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th>Published Date <a class="tip" rel="tooltip" href="#" title=
"&lt;b&gt;Published Date&lt;/b&gt; - The date that a drug label is published on DailyMed for public view. This is distinct from &lt;b&gt;Updated Date&lt;/b&gt;*. &lt;br&gt;&lt;br&gt; *&lt;b&gt;Updated Date&lt;/b&gt; (also known as &lt;b&gt;Effective Time&lt;/b&gt;) - The label revision date included in the SPL.">
(What is this?)</a></th>
<th>Version</th>
<th>Files</th>
</tr>
<tr>
<td>Dec 16, 2015</td>
<td>11 (current)</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=196755">download</a></td>
</tr>
<tr>
<td>Nov 25, 2015</td>
<td>10</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=194707">download</a></td>
</tr>
<tr>
<td>Mar 26, 2015</td>
<td>8</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=170206">download</a></td>
</tr>
<tr>
<td>May 9, 2014</td>
<td>6</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=139289">download</a></td>
</tr>
<tr>
<td>Oct 22, 2013</td>
<td>5</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=122022">download</a></td>
</tr>
<tr>
<td>Dec 23, 2010</td>
<td>(5)</td>
<td></td>
</tr>
<tr>
<td>Jan 11, 2010</td>
<td>4</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=15275">download</a></td>
</tr>
<tr>
<td>Jun 30, 2009</td>
<td>3</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=10928">download</a></td>
</tr>
<tr>
<td>Jun 12, 2008</td>
<td>2</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=8328">download</a></td>
</tr>
<tr>
<td>Dec 18, 2007</td>
<td>1</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=6420">download</a></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- RxNorm Modal -->
<div class="mfp-hide modal" id="modal-rx-norm">
<div class="modal-wrapper">
<header>
<h2>RxNorm</h2>
</header>
<div class="top">
<h3 class="long-title">KETEK- telithromycin tablet, film
coated<br></h3>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th></th>
<th>RxCUI</th>
<th>RxNorm NAME</th>
<th>RxTTY</th>
</tr>
<tr class="psn-rxtty">
<td>1</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=388510">388510</a></td>
<td>telithromycin 400 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>2</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=388510">388510</a></td>
<td>telithromycin 400 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>3</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=539741">539741</a></td>
<td>Ketek 400 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>4</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=539741">539741</a></td>
<td>telithromycin 400 MG Oral Tablet [Ketek]</td>
<td>SBD</td>
</tr>
<tr>
<td>5</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=539741">539741</a></td>
<td>Ketek 400 MG Oral Tablet</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>6</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=597761">597761</a></td>
<td>telithromycin 300 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>7</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=597761">597761</a></td>
<td>telithromycin 300 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>8</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=602855">602855</a></td>
<td>Ketek 300 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>9</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=602855">602855</a></td>
<td>telithromycin 300 MG Oral Tablet [Ketek]</td>
<td>SBD</td>
</tr>
<tr>
<td>10</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=602855">602855</a></td>
<td>Ketek 300 MG Oral Tablet</td>
<td>SY</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- Label RSS Modal -->
<div class="mfp-hide modal" id="modal-label-rss">
<header>
<h2>Get Label RSS Feed for this Drug</h2>
</header>
<div class="top">
<h3 class="long-title">KETEK- telithromycin tablet, film
coated<br></h3>
</div>
<div class="modal-content">
<h4>To receive this label RSS feed</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href=
"https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=4471223e-9023-457e-be2e-8e4e0c2d94d1"
target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=4471223e-9023-457e-be2e-8e4e0c2d94d1</a></p>
<h4>To receive all DailyMed Updates for the last seven days</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>
<h4>What will I get with the DailyMed RSS feed?</h4>
<p>DailyMed will deliver notification of updates and additions to
Drug Label information currently shown on this site through its RSS
feed.</p>
<p>DailyMed will deliver this notification to your desktop, Web
browser, or e-mail depending on the RSS Reader you select to use.
To view updated drug label links, paste the RSS feed address (URL)
shown below into a RSS reader, or use a browser which supports RSS
feeds, such as Safari for Mac OS X.</p>
<h4>How to discontinue the RSS feed</h4>
<p>If you no longer wish to have this DailyMed RSS service, simply
delete the copied URL from your RSS Reader.</p>
<a href="/dailymed/rss-updates.cfm" class="rss-icon"></a> <a href=
"/dailymed/rss-updates.cfm">More about getting RSS News &amp;
Updates from DailyMed</a></div>
</div>
<!-- RxImage no more notification modal -->
<div class="mfp-hide modal" id="no-pill-photo-warning-modal">
<div class="modal-content">
<h4>Why is DailyMed no longer displaying pill images on the Search
Results and Drug Info pages?</h4>
<br>
<p>Due to inconsistencies between the drug labels on DailyMed and
the pill images provided by <a href=
"https://rximage.nlm.nih.gov/docs/doku.php?id=rximageapi_support"
target="_blank">RxImage</a>, we no longer display the RxImage pill
images associated with drug labels.</p>
<p>We anticipate reposting the images once we are able identify and
filter out images that do not match the information provided in the
drug labels.</p>
</div>
</div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<div class="mobilenav no-js">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
<footer class="mainFooter">
<div class="container">
<div class="three columns">
<div class="nihnlmlogoprint"><img src=
"/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>
<a href="//www.nlm.nih.gov/" class="logo" title=
"National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png"
width="109" height="37" alt=
"National Library of Medicine | National Institutes of Health"
title=
"National Library of Medicine | National Institutes of Health"></a></div>
<div id="share" class="thirteen columns">
<div class="footer-links">
<ul class="primary">
<li><a href="/dailymed/about-dailymed.cfm" title=
"About DailyMed">About DailyMed</a><span>|</span></li>
<li><a href="/dailymed/contact-us.cfm" title="Contact Us">Contact
Us</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/copyright.html" title="Copyright"
target="_blank" rel="bookmark">Copyright</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/privacy.html" title="Privacy"
target="_blank" rel="bookmark">Privacy</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/accessibility.html" title=
"Web Accessibility" target="_blank" rel="bookmark">Web
Accessibility</a></li>
</ul>
<ul class="secondary">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">National Institutes of Health</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">U.S. National Library of Medicine</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<ul class="secondary mobile">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">NIH</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">NLM</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<div class="social">Share <!-- AddThis Button BEGIN -->
 <noscript>: JavaScript needed for Sharing tools</noscript>
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AKETEK%2D%20Telithromycin%20Tablet%2C%20Film%20Coated%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D4471223e%2D9023%2D457e%2Dbe2e%2D8e4e0c2d94d1%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="width: 16px; height: 16px"><span style=
"left: -9999px; position: absolute;">Bookmark &amp; Share</span>
<img style="width:17px; margin-top: -2px;" src=
"/dailymed/images/addthis-image.jpg" alt=
"Bookmark &amp; Share"></a></div>
<!-- AddThis Button END --></div>
</div>
</div>
</div>
<div class="divider"></div>
</footer>
<div class="divider"></div>
</div>
<div class="to-top"></div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<script type="text/javascript" src=
"//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery == 'undefined')
        {  
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');
        }
</script> <script type="text/javascript">
        var basepath = "/dailymed";
;
        var availableClasses =  new Array();
;
        for(var i = 0; i < availableClasses.length; i++){
                availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();
        }
        var labeltitle = "KETEK- telithromycin tablet, film coated <br>";
;
        var emailLink = "";
;
        var emailrequest = "0";
;
</script> <script src=
"/dailymed/scripts/javascript-html-attribute-encoding.min.js">
</script> <script src="/dailymed/scripts/spin.min.js">
</script> <script src="/dailymed/scripts/scripts.min.js?v=2">
</script> <script type='text/javascript' src=
"//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery.ui == 'undefined')
        {
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');
            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="/dailymed/css/jquery-ui-1.10.4.custom.min.css">');
        }
        else{
            document.write('<link rel="stylesheet" href="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');
        }
</script> <script type='text/javascript' src=
'/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'>
</script> <script type="text/javascript" src=
"/dailymed/scripts/jquery.placeholder.min.js">
</script> <script src=
"//www.accessdata.fda.gov/spl/stylesheet/spl.js" type=
"text/javascript" charset="utf-8">
/* */
</script> <!-- Magnific Popup core JS file -->
 <script src="/dailymed/scripts/jquery.magnific-popup.min.js">
</script> <script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <script>
 var ignore_onbeforeunload = false;

 $("a").on('click',function(){
    if(ignore_onbeforeunload){
        ignore_onbeforeunload = false;
    }
})

$("a[href^='mailto'], a[href$='zip']").on('click',function(){
    ignore_onbeforeunload = true;
});


$(window).on('beforeunload', function(){
    if (!ignore_onbeforeunload){
        // Only run the loading icon if changing the page takes longer than 200ms
        setTimeout(function(){
            // Fade in the grey screen
            $('body').prepend($('<div class="loading-wrapper" style="width: 100%;height: 100%;background-color: rgba(0, 0, 0, 0.50);position: fixed;top:0;z-index: 100000;"><\/div>').fadeIn('fast'));
            var opts = {
                  lines: 12 // The number of lines to draw
                , length: 14 // The length of each line
                , width: 5 // The line thickness
                , radius: 14 // The radius of the inner circle
                , scale: 1 // Scales overall size of the spinner
                , corners: 1 // Corner roundness (0..1)
                , color: '#fff' 
                , opacity: 0.25 // Opacity of the lines
                , rotate: 0 // The rotation offset
                , direction: 1 // 1: clockwise, -1: counterclockwise
                , speed: 1 // Rounds per second
                , trail: 60 // Afterglow percentage
                , fps: 20 // Frames per second when using setTimeout() as a fallback for CSS
                , zIndex: 2e9 // The z-index (defaults to 2000000000)
                , className: 'spinner' // The CSS class to assign to the spinner
                , top: '50%' // Top position relative to parent
                , left: '50%' // Left position relative to parent
                , shadow: false // Whether to render a shadow
                , hwaccel: false // Whether to use hardware acceleration
                , position: 'absolute' // Element positioning
                }
            var spinner = new Spinner(opts).spin();
            $('.loading-wrapper').append(spinner.el);
        }, 200);
    }

    //ignore_onbeforeunload = false;
});
</script> <!-- START OF SmartSource Data Collector TAG -->
<!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. -->
<!-- Version: 9.4.0 -->
<!-- Tag Builder Version: 3.3  -->
<!-- Created: 1/25/2012 11:57:33 PM -->
<script type="text/javascript" src=
"/dailymed/scripts/webtrends.min.js">
</script> 
<!-- =================================================================================== -->
<!-- Warning: The two script blocks below must remain inline. Moving them to an external -->
<!-- JavaScript include file can cause serious problems with cross-domain tracking.      -->
<!-- =================================================================================== -->
<script type="text/javascript">
//<![CDATA[
var _tag=new WebTrends();
_tag.dcsGetId();
//]]>
</script> <script type="text/javascript">
//<![CDATA[
_tag.dcsCustom=function(){
// Add custom parameters here.
//_tag.DCSext.param_name=param_value;
_tag.DCSext.dcsid=_tag.dcsid
}
_tag.trackAllEvents=true;
_tag.dcsCollect();
//]]>
</script> <noscript>
<div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src=
"//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"></div>
</noscript> <!-- END OF SmartSource Data Collector TAG -->
 <script type="text/javascript">
    setTimeout(function(){var a=document.createElement("script");
    var b=document.getElementsByTagName("script")[0];
    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);
    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);
</script> <script type="text/javascript">
    function getParameterByName(name) {
        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");
        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),
            results = regex.exec(location.search);
        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));
    }
    /* Tracking label type on search pages */
    function CE_READY() {
        if(!getParameterByName('labeltype')){
           CE2.set(1, "No Label Type");
        }
        else{
            var labeltype = getParameterByName('labeltype');
            if(labeltype == 'all'){
                CE2.set(1, "All");
            }
            else if(labeltype == 'human'){
                CE2.set(1, "Human");
            }
            else if(labeltype == 'animal'){
                CE2.set(1, "Animal");
            }
            else{
                CE2.set(1, "Unknown");
            }
        }
    }
</script> <!-- DAP Universal Analytics -->
 <script language="javascript" id="_fed_an_ua_tag" src=
"/dailymed/scripts/Universal-Federated-Analytics-Min.2.01.js?agency=HHS&amp;subagency=NIH&amp;enhlink=true&amp;dclink=true">
</script> <script src="/dailymed/scripts/preview-text.min.js">
</script>
</body>
</html>
